Non-Coding RNAs in Cancer Radiosensitivity: MicroRNAs and lncRNAs as Regulators of Radiation-Induced Signaling Pathways

Marta Podralska 1, Sylwia Ciesielska 2, Joost Kluiver 3, Anke van den Berg 3,†, Agnieszka Dzikiewicz-Krawczyk 1,*,† and Izabella Slezak-Prochazka 4,*,†

1 Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznań, Poland; marta.podralska@igcz.poznan.pl
2 Department of Systems Biology and Engineering, Faculty of Automatic Control, Electronics and Computer Science, Silesian University of Technology, 44-100 Gliwice, Poland; sylwia.ciesielska@polsl.pl
3 Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, 9700RB Groningen, The Netherlands; j.l.kluiver@umcg.nl (J.K.); a.van.den.berg01@umcg.nl (A.v.d.B.)
4 Biotechnology Centre, Silesian University of Technology, 44-100 Gliwice, Poland
* Correspondence: agnieszka.dzikiewicz-krawczyk@igcz.poznan.pl (A.D.-K.); izabella.slezak-prochazka@polsl.pl (I.S.-P.); Tel.: +48-061-657-9219 (A.D.-K.); +48-032-237-2769 (I.S.-P.)
† These authors contributed equally to this work.

Received: 8 May 2020; Accepted: 21 June 2020; Published: 23 June 2020

Abstract: Radiotherapy is a cancer treatment that applies high doses of ionizing radiation to induce cell death, mainly by triggering DNA double-strand breaks. The outcome of radiotherapy greatly depends on radiosensitivity of cancer cells, which is determined by multiple proteins and cellular processes. In this review, we summarize current knowledge on the role of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in determining the response to radiation. Non-coding RNAs modulate ionizing radiation response by targeting key signaling pathways, including DNA damage repair, apoptosis, glycolysis, cell cycle arrest, and autophagy. Additionally, we indicate miRNAs and lncRNAs that upon overexpression or inhibition alter cellular radiosensitivity. Current data indicate the potential of using specific non-coding RNAs as modulators of cellular radiosensitivity to improve outcome of radiotherapy.

Keywords: non-coding RNA; miRNA; lncRNA; circRNA; radiation response; radiotherapy

1. Introduction

Radiation therapy is a common treatment for many types of cancer, either alone or in combination with other therapeutic approaches. Different tumor types vary in their sensitivity to radiotherapy [1]. The response to radiation treatment is mediated by cellular processes such as DNA damage repair, apoptosis, cell cycle redistribution, etc., and some tumors exhibit high level of radioresistance. For an effective treatment, patients with radioresistant tumors require higher doses of irradiation which will lead to undesired side effects. Identification of factors leading to radioresistance and markers of radiosensitivity is crucial for identifying responsive patients and improving the outcome of radiotherapy. Recently, it has been demonstrated that expression patterns of non-coding RNAs (ncRNAs) after ionizing radiation (IR) differ between radioresistant and radiosensitive tumors [2–7].

Non-coding RNAs are a diverse group of functional RNA molecules that are not translated into proteins. Non-coding RNAs are predominant in the genome and can be divided into housekeeping ncRNAs, such as transfer RNAs (tRNA) and ribosomal RNAs (rRNA), and regulatory ncRNAs,
which can be divided into small (<200 nt) ncRNAs, including microRNAs (miRNAs), and long (>200 nt) ncRNAs (IncRNAs) [8]. miRNAs are single-stranded, ~22 nt long ncRNAs that bind to a short core sequence mainly in the 3′ untranslated region (UTR) of target messenger RNA (mRNA) and lead to inhibition of translation or mRNA degradation [9,10]. IncRNAs are the largest class of ncRNAs with currently a total of >90,000 annotated genes [11]. A subset of the IncRNAs are circular RNAs (circRNAs) that are formed during splicing of linear transcripts (both protein coding and non-coding) into covalently closed single-stranded RNA molecules [12]. Regulation of gene expression by IncRNAs is more complex as they can interact with DNA, RNA, or proteins and act as transcriptional modulators, RNA splicing regulators, microRNA sponges, RNA-binding protein (RBP) sponges, and scaffolds to form ribonucleoprotein complexes [13–15]. Aberrant miRNA and IncRNA expression signatures have been reported for most cancer types and some of these ncRNAs were shown to impact on cellular functions such as cell proliferation and resistance to apoptosis.

Current studies revealed several mechanisms through which ncRNAs contribute to response to radiotherapy. Here, we summarize the main findings on ncRNAs involved in crucial pathways in response to radiotherapy in cancer. We focused on miRNAs and IncRNAs that regulate DNA double strand breaks (DSBs) repair, apoptosis, autophagy, cell cycle progression, glycolysis and Wnt/β-catenin pathway in response to IR. We also present an overview of ncRNAs that alter radiosensitivity of cancer cells (Tables 1 and 2) and discuss the utilization of ncRNAs to improve the outcome of radiotherapy.

| miRNA   | Target   | Pathway   | Cancer Type       | Reference   |
|---------|----------|-----------|-------------------|-------------|
| let-7   | Cyclin D1 | Cell cycle | Uveal melanoma *, breast cancer | [16,17]    |
| miR-16  | Cyclin D1 | Cell cycle | Prostate cancer   | [18]        |
| miR-18a | ATM      | DSB repair | Breast cancer, lung cancer * | [19,20]    |
|         | HIF-1α   | -         | Lung cancer *     | [20]        |
| miR-22  | SIRT1    | Apoptosis  | Breast cancer     | [21]        |
| miR-23b | ATG12    | Autophagy  | Pancreatic cancer * | [22]       |
| miR-24  | H2AX     | DSB repair | Leukemia          | [23]        |
| miR-26a | ATM      | DSB repair | Glioma            | [24]        |
| miR-26b | DRAM1    | Autophagy  | Breast cancer     | [25]        |
| miR-30a | TP53INP1 | Autophagy  | Prostate cancer   | [26]        |
| miR-33a | HIF-1α   | Glycolysis | Melanoma *        | [27]        |
| miR-34a | LygDI    | Apoptosis  | NSCLC             | [28]        |
|         | RAD51    | DSB repair | Lung cancer *     | [29]        |
| miR-99a | mTOR     | Apoptosis  | NSCLC *           | [30]        |
| miR-100 | ATM      | -         | Glioma            | [31]        |
| miR-101 | DNA-PKcs | -         | Glioma *          | [32]        |
|         | ATM      | -         | Glioma *          | [32]        |
|         | STMN1    | Autophagy  | NPC               | [33]        |
| miR-107 | RAD51    | DSB repair | Ovarian cancer    | [34]        |
| miR-124 | CDK4     | Apoptosis  | Glioma, ESCC      | [35,36]     |
|         | STAT3    | Apoptosis  | NSCLC *, breast cancer | [37,38]   |
|         | PIM 1    | -         | Prostate cancer   | [39]        |
| miR-125a| p21      | -         | Cervical cancer   | [40]        |
| miR-125b| c-Jun    | Apoptosis  | Breast cancer     | [41]        |
| miR-133a| EGFR     | Apoptosis  | ESCC              | [42]        |
| miR-133b| PKM2     | Glycolysis | NSCLC             | [43]        |
| miR-136 | E2F1     | Apoptosis  | Cervical cancer   | [44]        |
| miRNA  | Target                | Pathway               | Cancer Type                  | Reference |
|--------|-----------------------|-----------------------|------------------------------|-----------|
| miR-138 | H2AX                  | DSB repair            | Osteosarcoma                 | [45]      |
| miR-144 | PIM 1                 | -                     | Prostate cancer              | [39]      |
| miR-150 | AKT                   | Apoptosis             | NK/T cell lymphoma *         | [46]      |
| miR-153 | Bcl-2                 | Apoptosis             | Glioma *                     | [47]      |
| miR-155 | RAD51                 | DSB repair            | Triple negative breast cancer * | [48]    |
| miR-182 | BRCA1                 | DSB repair            | Breast cancer                | [49]      |
| miR-185 | Wnt2B                 | Wnt/β-catenin         | NPC                          | [50]      |
| miR-193a | Mcl-1                | Apoptosis             | GBM, cervical cancer         | [51]      |
| miR-199a | Beclin-1, DRAM1       | Autophagy             | Breast cancer                | [52]      |
| miR-200c | UBQLN1               | Autophagy             | Breast cancer                | [53]      |
| miR-203a | ATM                  | Apoptosis, cell cycle, migration | Ovarian cancer | [54] |
| miR-205 | TP53INP1             | Autophagy             | Prostate cancer              | [55]      |
| miR-214 | ATG12                | Autophagy             | CRC *                        | [56]      |
| miR-216a | Beclin-1             | Autophagy             | Pancreatic cancer *          | [57]      |
| miR-222 | RAD51                | DSB repair            | Ovarian cancer               | [58]      |
| miR-223 | ATM                  | -                     | Glioma *                     | [59]      |
| miR-301a | Wnt                  | Wnt/β-catenin, migration | ESCC                       | [60]      |
| miR-302a | AKT, RADS2           | -                     | Breast cancer *              | [61]      |
| miR-320a | STAT3                | Apoptosis, metastasis | NSCLC *                      | [62]      |
| miR-324-3p | Wnt2B             | Wnt/β-catenin         | NPC                          | [63]      |
| miR-421 | ATM                  | DSB repair            | SCC                          | [64]      |
| miR-448 | HIF-1α               | Glycolysis            | Glioma                       | [65]      |
| miR-449a | LDHA                | Glycolysis, apoptosis | Lung cancer                  | [66]      |
| miR-449a | c-MYC               | Cell cycle            | Prostate cancer *            | [67]      |
| miR-450a | DUSP10              | Autophagy             | ESCC *                       | [68]      |
| miR-634 | STAT3                | Apoptosis             | Prostate cancer *            | [69]      |
| miR-770 | PBK                  | Apoptosis             | CRC *                        | [70]      |
| miR-875 | EGFR                 | DSB repair            | Prostate cancer *            | [71]      |
| miR-1275 | Wnt1                | Wnt/β-catenin, EMT, ESCC | ESCC *                    | [72]      |
| miRNA Promoting Radioresistance |          |                      |                              |    |
Table 1. Cont.

| miRNA     | Target     | Pathway          | Cancer Type          | Reference |
|-----------|------------|------------------|----------------------|-----------|
| miR-205   | PTEN       | Apoptosis        | NPC                  | [83]      |
| miR-208a  | p21        |                  | Lung cancer          | [84]      |
| miR-210   | ALF/M3     | Apoptosis        | Hepatoma             | [85]      |
| miR-212   | BRCA1      | Apoptosis        | Glioma               | [86]      |
| miR-214   | PTEN       |                  | Ovarian cancer *     | [87]      |
| miR-221/miR-222 | PTEN | Apoptosis, migration | CRC, gastric cancer, GBM | [88–91] |
| miR-300   | p53, Apat-1| Apoptosis, cell cycle, senescence | Lung cancer | [92] |
| miR-301a  | TCEAL7     | Wnt/β-catenin, apoptosis | GBM *               | [93]      |
| miR-375   | p53        | Apoptosis, cell cycle | Gastric cancer       | [94]      |
| miR-498   | PTEN       | Apoptosis, migration | Prostate cancer      | [95]      |
| miR-622   | Rb         | Apoptosis        | CRC                  | [96]      |
| miR-1246  | mTOR       | Autophagy        | NSCLC                | [97]      |

* Effect on radiosensitivity/radioresistance observed in vivo; HNSCC—head and neck squamous cell carcinoma; HCC—hepatocellular carcinoma; NPC—nasopharyngeal carcinoma; CRC—colorectal cancer; NSCLC—non-small cell lung cancer; OSCC—oral squamous cell carcinoma; ESCC—esophageal squamous cell carcinoma; GBM—glioblastoma; NK/T-cell lymphoma—natural killer/T-cell lymphoma; DSB—DNA double strand break.

Table 2. Long non-coding RNAs (lncRNAs) promoting radiosensitivity or radioresistance in cancer cells.

| IncRNA     | Target     | Pathway          | Cancer Type          | Reference |
|------------|------------|------------------|----------------------|-----------|
| circATRNL1 | miR-23a/PTEN | Apoptosis, cell cycle | OSCC | [98] |
| lncRNA-p21 | β-catenin  | Wnt/β-catenin    | Gastric cancer       | [99]      |
| MEG3       | miR-182    | DSB repair       | Thyroid cancer       | [100]     |
| NEAT1      | miR-101/EMP2| Apoptosis, EMT   | NPC *                | [102]     |
| OIPS-AS1   | miR-369/DYRK1A| Apoptosis | CRC                  | [103]     |
| BOKAS      | WISP1      | Wnt/β-catenin    | ESCC                 | [104]     |
| BLACAT1    | PSEN1      | Apoptosis, cell cycle DSB repair | HNSCC | [105] |
| CCAT1      | miR-148    | Apoptosis        | Breast cancer        | [106]     |
| circPTX1   | miR-329-3p/NEK2| Glycolysis | Glioma *              | [107]     |
| circPTK2   | miR-369/ZEB1| Apoptosis        | Gastric cancer *     | [108]     |
| CRNDE      |            | Apoptosis        | Lung adenocarcinoma  | [109]     |
| CYTOR      |            | Apoptosis        | NSCLC                | [110]     |
| DNMDOS     |            | DSB repair       | ISCC *               | [111]     |
| FAM83H-AS1 | HuR        | DSB repair       | Ovarian cancer       | [112]     |
| HOTAIR     | p21        | Apoptosis, cell cycle | Cervical cancer *    | [113]     |
| mir-218    | Wnt/β-catenin | Apoptosis, cell cycle, DSB repair | Pancreatic cancer | [114] |
| LC3-II, ATG7|            | Autophagy, apoptosis | Pancreatic cancer | [115] |
| HULC       | LC3B-II, Beclin-1 | Apoptosis, autophagy | Prostate cancer | [117] |
| LINC00963  | miR-324-3p/ACK1| DSB repair | Breast cancer        | [118]     |
| LINC02582  | miR-200c/USP7/CHK1| DSB repair | Breast cancer *      | [119]     |
| lincRNA-p21 | HIF-1α    | Autophagy        | Hepatoma, Glioma     | [120]     |
| lincRNA-ROR| P53, miR-145| Apoptosis        | CRC                  | [121]     |
Table 2. Cont.

| IncRNA   | Target           | Pathway               | Cancer Type       | Reference |
|----------|------------------|-----------------------|-------------------|-----------|
| LINP1    | Ku80, DNA-PKcs   | Apoptosis, DSB repair | Cervical cancer   | [122]     |
| MALAT1   | Cks1             | Apoptosis             | ESCC *            | [123]     |
|          | miR-1/SLUG       | Apoptosis             | NPC *             | [124]     |
|          | miR-145          | Apoptosis, cell cycle | Cervical cancer   | [125]     |
| NEAT1    | miR-204/ZEB1     | Apoptosis             | NPC               | [126]     |
|          | miR-193b/Cyclin D1 | Apoptosis, cell cycle | Cervical cancer * | [127]     |
| PCAT6    | miR-185/TPD52    | Apoptosis, cell cycle | Breast cancer     | [128]     |
| POU6F2-AS2 | YBX1            | DSB repair           | ESCC              | [129]     |
| PVT1     | miR-195          | Apoptosis, DSB repair | NSCLC *           | [130]     |
| ATM, p53, CHK2   |                   | Apoptosis, DSB repair | NPC *             | [131]     |
| HIF-1α   |                   | DSB repair           | NPC               | [132]     |
| SBF2-AS1 | miR-302a/MBNL3   | Apoptosis             | NSCLC *           | [133]     |
| TP73-AS1 | PTEN, AKT        | Apoptosis             | HCC *             | [134]     |
| TUG1     | HMGB1            | Apoptosis             | Bladder cancer *  | [135]     |
| UCA1     | AKT, FAK, FGR, AMPKa1 | Cell cycle           | Gastric cancer    | [136]     |
| UCA1     | HK2              | Glycolysis            | Cervical cancer   | [137]     |

* Effect on radiosensitivity/radioresistance observed in vivo; HNSCC—head and neck squamous cell carcinoma; HCC—hepatocellular carcinoma; NPC—nasopharyngeal carcinoma; CRC—colorectal cancer; NSCLC—non-small cell lung cancer; OSCC—oral squamous cell carcinoma; ESCC—esophageal squamous cell carcinoma; lincRNA—long intergenic noncoding RNA.

2. ncRNAs Involved in DSB Repair

DNA double strand breaks (DSBs) are the most prevalent and deleterious type of damage induced by IR. If not repaired correctly, it can lead to cell death or chromosomal aberrations and genomic instability. Cells use two major mechanisms to repair DSBs, the non-homologous end joining (NHEJ) and homologous recombination (HR) pathways. The NHEJ pathway ligates broken DNA ends directly, whereas HR employs a homologous DNA template from the sister chromatid [138]. Both pathways require several proteins, which cooperate to detect (ATM, ATR, CHK1, CHK2), signal (γH2AX) and repair DSBs (BRCA1, BRCA2, Ku80, DNA-PKcs) [139,140]. Recently, the role of ncRNAs in DSB repair has been recognized [141]. Here, we summarize ncRNAs involved in DSB repair following IR (Figure 1).

2.1. miRNAs

Two miRNAs, miR-24, and miR-138 were shown to directly regulate H2AX upon IR. Phosphorylated H2AX (γH2AX) foci are early markers of DSBs, since H2AX recruits DNA repair proteins to DSB damage sites [142]. Overexpression of miR-24 decreased H2AX levels resulting in a diminished capacity to repair DSBs upon γ-irradiation in differentiated leukemic cells. DSB repair was restored by overexpressing a miR-24-insensitive H2AX gene [23]. A similar effect was shown in osteosarcoma cells where miR-138 mimics reduced formation of γH2AX foci, increased genomic instability and enhanced cellular sensitivity to IR [45].
was downregulated by miR-18a in breast cancer, miR-26a in glioma and miR-421 in squamous cell carcinoma (SCC) [19,24,63]. BRCA1, another important protein in HR, was suppressed by miR-182 in breast cancer cells [49]. The HR pathway was also impaired by miR-875 which directly targeted epidermal growth factor receptor (EGFR) and inhibited the EGFR-ZEB1-CHK1 axis. Overexpression of miR-875 enhanced radiosensitivity in prostate cancer cells in vitro and in xenograft models through targeting EGFR [70].

Several miRNAs were reported to sensitize cells to radiotherapy by inhibiting expression of proteins involved in the HR pathway. A key player in HR, ataxia telangiectasia mutated (ATM), was downregulated by miR-18a in breast cancer, miR-26a in glioma and miR-421 in squamous cell carcinoma (SCC) [19,24,63]. BRCA1, another important protein in HR, was suppressed by miR-182 in breast cancer cells [49]. The HR pathway was also impaired by miR-875 which directly targeted epidermal growth factor receptor (EGFR) and inhibited the EGFR-ZEB1-CHK1 axis. Overexpression of miR-875 enhanced radiosensitivity in prostate cancer cells in vitro and in xenograft models through targeting EGFR [70].

Several studies showed a miRNA-mediated regulation of RAD51 expression and the subsequent formation of RAD51 foci in response to IR, an important step in HR. RAD51 was identified as a direct target of miR-34a, miR-107, miR-155 and miR-222 upon IR. Overexpression of miR-34a in lung cancer cells reduced formation of radiation-induced RAD51 foci. This phenotype could be rescued by RAD51 reintroduction. In mouse models administration of MRX34, a liposomal nanoparticle loaded with miR-34a mimics, sensitized lung tumors to radiation by repressing RAD51 [29]. A similar effect was observed for miR-107 and miR-222 mimics in ovarian cancer cells and for overexpression of miR-155 in breast cancer cells [34,48]. Additionally, high miR-155 levels were associated with lower RAD51 expression and better overall survival of patients in a large series of triple-negative breast cancers [48].

2.2. lncRNAs

PVT1 was upregulated in patients with nasopharyngeal carcinoma (NPC). PVT1 knockdown enhanced radiosensitivity of NPC cells in vitro and in vivo, which could be attributed to increased apoptosis rate after IR. Decreased phosphorylation of key mediators of DNA damage response, i.e., ATM, p53 and CHK2, was observed in irradiated NPC cells with PVT1 knockdown [131]. This suggests impaired DSB repair upon PVT1 knockdown, however, the level and repair dynamics of IR-induced DSBs was not studied. Wang et al. further showed that PVT1 increased stability of HIF-1α in NPC cells [132]. PVT1 acted as a scaffold for histone acetyltransferase KAT2A, which promoted H3K9 acetylation at the promoter of NF90, a known regulator of HIF-1α expression and stability.

Two lncRNAs, POUSF2-AS2 and DNM3OS, were involved in DSB repair in esophageal squamous cell carcinoma (ESCC). Downregulation of POUSF2-AS2 and DNM3OS promoted radiosensitivity of ESCC cells and impaired DSB repair [111,129]. Analysis of proteins interacting with POUSF2-AS2 revealed among others YBX1, a RNA and DNA binding protein involved in DNA damage response.
Ectopic expression of YBX1 partially rescued sensitivity to IR caused by POU6F2-AS2 knockdown, indicating a functional link between POU6F2-AS2 and YBX1 in IR response. Furthermore, it was demonstrated that POU6F2-AS2 is required for YBX1 binding to chromatin, especially to the sites of DNA breaks [129]. DNM3OS knockdown increased the extent of IR-induced DNA damage and impaired DSB repair, as demonstrated by the higher number of γH2AX foci after IR, higher tail moment in comet assay and reduced induction of DNA repair proteins. Interestingly, expression of DNM3OS and radioresistance were promoted by cancer-associated fibroblasts, which are an important component of the tumor environment in ESCC [111].

LINP1 transcripts are localized predominantly in the cytoplasm of Hela S3 cells, but are upregulated and rapidly translocated to the nucleus after IR. Knockdown of LINP1 enhanced radiosensitivity of cervical cancer cells by increasing apoptosis and impairing DSB repair after IR. RNA pulldown revealed association of LINP1 with Ku80 and DNA-PKcs, which suggests that LINP1 is involved in the NHEJ pathway. However, the effect of LINP1 knockdown on Ku80 and DNA-PKcs function was not investigated [122].

Several lncRNAs involved in repair of IR-induced DNA damage interacted with miRNAs. LINC02582 was identified as a direct target of miR-200c in breast cancer, and it promoted radioresistance of breast cancer cells in vitro and in vivo. Upon LINC02582 silencing, the number of irradiation-induced γH2AX foci increased and they persisted longer, which indicated that LINC02582 is involved in DSB repair. Further analysis revealed an interaction of LINC02582 with USP7, a deubiquitinating enzyme stabilizing among others the CHK1 kinase, a crucial player in DNA damage repair. The authors proved that LINC02582 stabilizes CHK1 via USP7 and demonstrated the significance of the miR-200c/LINC02582/USP7/CHK1 axis in radioresistance of breast cancer cells [119].

Other lncRNA–miRNA interactions reported in DNA damage repair include LINC00963 with miR-324-3p and HOTAIR with miR-218 in breast cancer, and MEG3 with miR-182 in thyroid cancer [101,115,118]. miR-218 and miR-182 counteracted the effect of their respective target lncRNAs on DNA damage repair.

3. ncRNAs Regulating IR-Induced Apoptosis

After exposure to IR, cell death regulatory pathways are activated to eliminate cells with extensive burden of DNA damage [143]. In case repair of IR-induced DNA damage fails, the p53-Induced Death Domain Protein 1 (PIDD) protein is activated in a p53-dependent manner and together with Death Adaptor Molecule RAIDD and caspase-2 this serves as an activation platform for further factors [144,145]. Consequently, cytochrome c is released from damaged mitochondria and activation of caspase-9 triggers a cascade of effector caspsases [146]. Several recent studies showed that ncRNAs can modulate programmed cell death after IR [147,148]. Apoptosis is an acclaimed indicator of cellular radiosensitivity and a prognostic factor of radiotherapy treatment outcome [149,150]. Apart from apoptosis, cell death after IR can also occur via necrosis and mitotic catastrophe. However, the evidence for the role of ncRNA in these processes in response to IR in cancer cells is limited. Below we present an overview of the ncRNAs involved in modulation of apoptosis after IR (Figure 2).
Figure 2. ncRNAs regulating IR-induced apoptosis. ncRNAs promoting (green) or inhibiting apoptosis (red). Pro-apoptotic genes are indicated in green and anti-apoptotic in red.

3.1. miRNAs

Three miRNAs were shown to modulate IR-induced apoptosis by targeting the TP53 gene or p53 associated proteins. p53 is a crucial tumor suppressor activated in response to IR to induce either cell cycle arrest or apoptosis [151]. miR-375 directly targeted p53. Overexpression of miR-375 reduced p53 expression, enhanced radioresistance, and abrogated p53-mediated apoptosis in IR-treated gastric cancer cells [94]. Apoptotic protease activating factor-1 (Apaf-1), the structural core of the apoptosome, was shown to be directly regulated by miR-300 in lung cancer cells. Ectopic expression of miR-300 caused radioresistance mediated at least in part by a reduction of Apaf-1-induced apoptosis [92]. Wu et al. showed that p21 protein, a target of p53, was downregulated by miR-17 in oral squamous cell carcinoma (OSCC) cells. Suppression of miR-17 in xenograft tumors resulted in increased p21 expression, increased apoptosis rate and enhanced radiosensitivity [72]. miR-210 increased radioresistance of hypoxic hepatoma cells by targeting apoptosis-inducing factor mitochondria-associated 3 (AIFM3) [85]. Downregulation of miR-210 promoted and AIFM3 inhibition attenuated IR-induced apoptosis in hypoxic hepatoma cells. miR-622 was shown to prevent apoptosis by inhibiting the retinoblastoma (Rb) tumor suppressor gene in colorectal cancer cells [96]. The Rb protein can either inhibit or promote apoptosis [152]. The pro-apoptotic role of Rb is associated with Rb-phosphorylation that induces formation of the pRb-E2F1-P/CAF complex. Increased miR-622 levels induced radioresistance, which could be reversed by restoration of Rb. miR-622-mediated Rb inhibition prevented the formation of pRb-E2F1-P/CAF complex [96]. Another miRNA acting on the same pathway, but via targeting E2F1 is miR-136. Similarly to Rb, E2F1 can also induce or inhibit apoptosis depending on the proteins it is associated with [153]. The anti-apoptotic role of E2F1 exerted through the NF-κB signaling pathway was inhibited by miR-136. Overexpression of miR-136 increased radiosensitivity by promoting apoptosis, and inhibition of proliferation in cervical cancer cells [44].
Two miRNAs were shown to affect IR-induced apoptosis by targeting two main anti-apoptotic proteins. Bcl-2 was directly targeted by miR-153 in glioma cells. Levels of miR-153 were lower in radioresistant glioma clinical specimens and glioma cell lines exposed to IR. Overexpression of miR-153 promoted radiosensitivity and apoptosis in glioma cells. This effect was modulated by Bcl-2 inhibition, since restoration of Bcl-2 expression reversed the miR-153-induced phenotype. Additionally, miR-153 enhanced the response to IR in xenograft mice [47]. Another pro-apoptotic miRNA, miR-193a, targeted Mcl-1. Overexpression of miR-193a resulted in increased apoptosis and DNA damage in glioblastoma (GBM) and cervical cancer cells. This effect could be blocked by antioxidant treatment, indicating the crucial role of ROS. Importantly, ectopic expression of Mcl-1 suppressed the pro-apoptotic action of miR-193a, suggesting that Mcl-1 depletion is critical for miR-193a-induced apoptosis [51].

The radiation-inducible miR-770 boosted apoptosis via direct targeting of PDZ-binding kinase (PBK), which sensitized colorectal cancer (CRC) cells to radiation both in vitro and in vivo [69]. Similarly, radiosensitivity and apoptosis were induced by miR-22-mediated inhibition of SIRT1 in breast cancer cells, by miR-34a-mediated inhibition of LyGDI in non-small cell lung cancer (NSCLC) cells and by miR-124-mediated inhibition of CDK4 in ESCC and glioma cells [21,28,35,36]. Moreover, restoration of SIRT and CDK4 reversed the phenotypes [21,35].

Several miRNAs exert their effects on IR response via targeting components of crucial survival pathways, i.e., extracellular signal-regulated kinase (ERK), Janus kinase/signal transducer and activator of transcription (JAK/STAT) and phosphoinositide 3-kinase (PI3K)/AKT. These pathways are initiated in response to IR-dependent activation of EGFR [154]. The ERK pathway was abrogated by the miR-133a-dependent inhibition of EGFR. This led to apoptosis and enhanced radiosensitivity of esophageal cancer cells [42]. Another main player of the ERK pathway, c-Jun is targeted by miR-125b. Forced expression of miR-125b in breast cancer cells resulted in radiosensitivity, enhanced apoptotic activity and senescence upon IR. Restored c-Jun abrogated miR-125b-mediated radiosensitization [41]. STAT3, one of the main players in the JAK/STAT pathway, is a direct target of miR-124, miR-320a and miR-634 [37,60,68]. Overexpression of miR-124 reduced the activity of STAT3 signaling pathway and enhanced apoptosis upon irradiation in NSCLC and in HER2-positive breast cancer [37,38]. In line with these findings, low miR-124 and high STAT3 levels were associated with a poor response to radiotherapy in HER2-positive breast cancer patients [38]. Ectopic expression of miR-320a enhanced IR-induced apoptosis and radiosensitivity of NSCLC cells both in vitro and in vivo [60]. Overexpression of miR-634 promoted apoptosis in irradiated breast cancer cells [68].

High activity of the PI3K/AKT pathway has been associated with resistance to IR-induced apoptosis in many cancer types [155]. AKT was reported to be directly targeted by miR-150 in natural killer (NK)/T-cell lymphoma cells. Overexpression of miR-150 promoted IR-induced apoptosis by suppressing PI3K/AKT signaling and sensitized NK/T-cell lymphoma cells to radiotherapy in a xenograft mouse model [46]. Furthermore, miR-203a-mediated ATM downregulation induced apoptosis and cell cycle arrest in G1 phase in ovarian cancer cells by inhibiting the AKT/GSK3β/Snail signaling pathway [54]. Another miRNA acting through the PI3K/AKT pathway in NSCLC is miR-99a. Ectopic miR-99a expression radiosensitized NSCLC cells in vitro and in vivo by reducing levels of mTOR, one of the downstream targets of AKT kinase [30].

Several miRNAs induce pro-survival signals in response to IR by targeting phosphatase and tensin homolog (PTEN), a primary inhibitor of the PI3K/AKT pathway. The currently known PTEN-targeting miRNAs include miR-17, miR-20a, miR-106b, miR-205, miR-221, miR-222, and miR-498. Overexpression of these miRNAs resulted in activation of the PI3K/AKT pathway, inhibited apoptosis and enhanced radioresistance [73,74,79,83,88,91,95,156]. Another miRNA that attenuated IR-induced apoptosis was miR-212 that directly targeted BRCA1 in glioma cells. Ectopically expressed miR-212 promoted radioresistance which could be phenocopied by BRCA1 knockdown [86].
3.2. lncRNAs

Several lncRNAs promoted radioresistance by inhibiting IR-induced apoptosis. Knockdown of lncRNA bladder cancer associated transcript 1 (BLACAT1) accelerated apoptosis of head and neck squamous cell carcinoma (HNSCC) by positively regulating expression of presenilin 1 protein (PSEN1). Levels of BLACAT1 and PSEN1 were also positively correlated in HNSCC patients. Overexpression of PSEN1 rescued the enhanced radiosensitivity observed upon BLACAT1 knockdown [105].

Radiation significantly elevated the expression of lncRNA TUG1 in bladder cancer cells. IR-induced apoptosis was noticeably enhanced upon TUG1 silencing and this was due to a downregulation of the anti-apoptotic HMGB1 protein. Restoration of HMGB1 expression reversed the pro-apoptotic effect of TUG1 knockdown [135].

Knockdown of lncRNA TP73-AS1 promoted apoptosis and thereby enhanced radiosensitivity of hepatocellular carcinoma (HCC) cells. This was mediated by upregulated PTEN levels and decreased AKT phosphorylation in HCC cells upon TP73-AS1 silencing. Moreover, knockdown of TP73-AS1 reduced tumor growth in vivo after IR [134].

LncRNA MALAT1 was downregulated after IR in ESCC cells. Overexpression of MALAT1 enhanced the radioresistance of ESCC cells. It was shown that MALAT1 prevented the downregulation of cyclin-dependent kinase subunit (Cks1) after IR, which resulted in a decrease in irradiation-induced apoptosis [123]. MALAT1 and several other lncRNAs also affected IR-induced apoptosis by interacting with miRNAs. In NPC, knockdown of MALAT1 promoted apoptosis and sensitized NPC cells to radiation both in vitro and in vivo. MALAT1 sequestered miR-1 and this resulted in increased levels of the anti-apoptotic SLUG protein [124]. In high risk HPV-positive cervical cancer knockdown of MALAT1 also enhanced IR-induced apoptosis. MALAT1 directly interacted with miR-145 and the combined knockdown of MALAT1 and overexpression of miR-145 had a stronger effect on apoptosis than miR-145 overexpression alone [125]. However, target genes of miR-145 relevant for the effect on apoptosis were not determined.

Contradictory effects of NEAT1 on IR-induced apoptosis were reported [102,126,127]. Wang et al. showed that NEAT1 is downregulated, while Lu et al. observed significantly upregulated levels of NEAT1 in NPC tissues. Wang et al. observed that knockdown of NEAT1 combined with radiation treatment significantly decreased apoptosis in NPC cells. NEAT1 enhanced the expression of the pro-apoptotic epithelial membrane protein 2 (EMP2) by sponging miR-101 [102]. On the contrary, in the study of Lu et al. NEAT1 downregulation reinforced radiosensitivity by enhancing apoptosis of NPC cells. In this case cellular radioresistance was regulated by the NEAT1/miR-204/ZEB1 axis [126]. The opposite effects of NEAT1 on radiosensitivity and IR-induced apoptosis in NPC cells are difficult to reconcile, possibly cell line-specific effects may be involved. In cervical cancer NEAT1 was highly expressed in radioresistant patients. Here, silencing of NEAT1 induced apoptosis in radioresistant cervical cancer cells. NEAT1 reduced miR-193b levels and enhanced expression of Cyclin D1, suggesting that NEAT1 can act as a competing endogenous RNA to sequester miR-193b [127].

Expression of long intergenic non-coding RNA-ROR (lincRNA-ROR) was elevated in CRC cell lines and tissue samples and further induced by IR. Knockdown of lincRNA-ROR enhanced radiosensitivity of CRC cells by increasing apoptosis after IR and it increased expression of p53 and miR-145, and affected the levels of p53/miR-145 targets: p21 and MYC [121].

In contrast to lincRNA-ROR, OIP5-AS1 was downregulated in CRC cell lines. OIP-AS1 dependent downregulation of miR-369 was shown to enhance radiosensitivity and IR-induced apoptosis. Downregulation of miR-369 led to increased levels of DYRK1A [105].

A miRNA-dependent mechanism was also described for lncRNA SBF2-AS1, which affected radiosensitivity of NSCLC through modulating miR-302a and its target MBNL3. Both silencing of SBF2-AS1 and overexpression of miR-302a decreased levels of MBNL3 and promoted apoptosis of NSCLC cells in vitro and in vivo. Furthermore, miR-302a binds to both SBF2-AS1 and MBNL3 indicating that the observed effect of SBF2-AS1 might be caused by sequestering miR-302a. In line
with the proposed mechanism, levels of SBF2-AS1 and MBNL3 were elevated, while miR-302a was downregulated in NSCLC tissues from radioresistant patients [133]. However, MBNL3 has not been reported previously to be involved in apoptosis, nor did the current study investigate how MBNL3 affects apoptosis.

PVT1 was another lncRNA promoting radioresistance of NSCLC cells. High levels of PVT1 were negatively correlated with miR-195 expression, and IR further increased PVT1 and reduced miR-195 levels. Direct interaction between PVT1 and miR-195 was demonstrated, and the effect of PVT1 inhibition on radiosensitivity and apoptosis was reversed by inhibition of miR-195 in vitro and in vivo [130]. The targets of miR-195 responsible for the effects on apoptosis remain to be identified.

CCAT1 was upregulated, while miR-148 was downregulated in radioresistant compared to radiosensitive breast cancer tissues. IR further increased CCAT and reduced miR-148 levels. Downregulation of CCAT1 enhanced caspase3 activity and induced apoptosis of breast cancer cells after IR. Direct interaction between miR-148 and CCAT1 was demonstrated, and overexpression of miR-148 copied the effect of CCAT1 knockdown on radiosensitivity and apoptosis in vitro and in vivo [106]. However, target genes of miR-148 relevant for apoptosis remain to be determined.

PCAT6 is an oncogenic lncRNA in various cancer types, among others in triple negative breast cancer (TNBC). Knockdown of PCAT6 enhanced radiosensitivity of TNBC cells via induction of apoptosis and G0/G1 cell cycle arrest. Further study revealed that PCAT6 interacted with miR-185 to promote expression of tumor protein D52 (TPD52) [128], an inhibitor of apoptosis overexpressed in several tumors [157].

Two circular RNAs have also been shown to modulate cancer cell radiosensitivity by sequestering miRNAs. circPTK2 was upregulated in gastric cancer tissues. IR further induced expression of circPTK2 in gastric cancer cell lines and its knockdown enhanced radiosensitivity by inducing apoptosis. Moreover, knockdown of circPTK2 reduced tumor growth in vivo. The effect on radiosensitivity and apoptosis was reversed by inhibition of miR-369 which directly interacts with circPTK2. ZEB1 was identified as the relevant target of miR-369, and its ectopic expression restored radioresistance and blocked apoptosis upon miR-369 overexpression [108].

circATRNL1 was downregulated in OSCC tissues. IR further reduced expression of circATRNL1 in OSCC cells, while its ectopic overexpression caused radiosensitization of OSCC cells by inducing apoptosis and promoting cell cycle arrest at G2 phase after IR. This effect was dependent on a direct interaction between circATRNL1 and miR-23a as shown by phenotype rescue experiments using miR-23a mimics. This was mediated by the miR-23a target gene PTEN which inactivates the AKT signaling pathway [98].

4. ncRNAs Involved in IR-Related Autophagy

In normal conditions autophagy is a well-controlled survival mechanism helping to recycle damaged proteins and cellular organelles. Induction of autophagy leads to formation of double-membrane vesicles called autophagosomes. This multistep process is controlled by a number of proteins, i.a. Beclin-1, LC3B-II, mTOR, and autophagy-related proteins (ATG). After fusion of the autophagosome with endosome and lysosome, the autolysosome is formed [158]. Then the autolysosome containing cytoplasm-derived contents is degraded together with its inner membrane by lysosomal hydrolases [158,159]. Autophagy induced by IR plays a crucial role in determining cell fate: whether cells survive or die and it also affects radiosensitivity [160]. On one hand, autophagy induced by radiation has a cytoprotective function allowing the cell to eliminate toxic species [161,162]. On the other hand, autophagy can enhance the anticancer effects of some drugs and serve as additional cell death pathway [162–164]. Below we present an overview of the ncRNAs currently known to be involved in regulation of IR-induced autophagy (Figure 3).
Figure 3. ncRNAs regulating IR-induced autophagy. ncRNAs and proteins promoting (green) or inhibiting (red) autophagy.

4.1. miRNAs

Two miRNAs directly regulate Beclin-1, a central regulator of autophagy that controls autophagosome nucleation and maturation [165]. Forced expression of miR-216a in radioresistant pancreatic cancer cells enhanced radiosensitivity by inhibiting autophagy in response to irradiation. These effects could be abrogated by overexpression of Beclin-1. Furthermore, miR-216a overexpression sensitized xenograft tumor to irradiation treatment by inhibiting IR-induced autophagy via targeting Beclin-1 [56]. Yi et al. showed that miR-199a mimic suppressed IR-induced autophagy in MCF7 breast cancer cells by targeting Beclin-1 and DNA damage-regulated autophagy modulator protein 1 (DRAM1) [52]. DRAM1 is also targeted by miR-26b in breast cancer cells and both overexpression of miR-26b and inhibition of DRAM1 reduced IR-induced autophagy [25].

miR-23b inhibited IR-induced autophagy by targeting ATG12, an ubiquitin-like protein involved in autophagy vesicles formation. Overexpression of miR-23b inhibited autophagy and sensitized pancreatic cancer cells to radiation. This effect was also confirmed in a xenograft model upon IR. In line with this, reduced levels of miR-23b resulted in increased levels of ATG12 and increased autophagy were observed in radioresistant compared to radiosensitive pancreatic cancer cells. Additionally, miR-23b expression inversely correlated with autophagy activity in human pancreatic cancer tissues [22]. Similarly, Hu et al. showed that miR-214 promoted radiosensitivity by targeting ATG12 and inhibiting IR-induced autophagy in CRC both in vitro and in vivo [55].

Several other miRNAs have been shown to inhibit IR-induced autophagy by targeting autophagy activators. MiR-200c targeted Ubiquilin-1 (UBQLN1), a promoter of autophagosome formation [166]. Ectopic expression of miR-200c sensitized breast cancer cells to irradiation via inhibition of autophagy. Inverse correlation between the levels of miR-200c, UBQLN1 and autophagy activity was observed in
human breast cancer tissues [53]. Another autophagy activator, Statmin 1 (STMN1) was identified as miR-101 target in NPC cells. Ectopic expression of miR-101 suppressed radiation-induced autophagy of NPC cells. This effect was reversed by STMN1 restoration [33]. A similar effect was shown for inhibition of Tumor protein 53-induced nuclear protein 1 (TP53INP1) by miR-30a and miR-205 in prostate cancer cells [26]. MiR-450a targeted DUSP10 and this impaired IR-induced autophagy by affecting the ERK pathway and regulating ROS elimination. Additionally, tumor xenograft experiments verified that miR-450a overexpression could increase sensitivity to radiotherapy in radioresistant ESCC cells in vivo [67].

One miRNA that promoted autophagy in NSCLC cells was miR-1246. Ectopic expression of miR-1246 downregulated mTOR and decreased radiosensitivity of lung cancer cells both in vitro and in vivo. Overexpression of mTOR reversed the effect [97].

4.2. lncRNAs

lincRNA-p21 was upregulated after IR and hypoxia treatment in hepatoma and glioma cells lines. The number of autophagic vesicles upon lincRNA-p21 knockdown was significantly decreased in hypoxic tumor cells. This effect was mediated by downregulation of HIF-1α and activation of the AKT/mTOR/p70S6K pathway. Moreover, overexpression of HIF-1α abolished the radiosensitizing effect of lincRNA-p21 knockdown [120].

HULC regulates sensitivity of prostate cancer cells to IR by modulating microtubule-associated protein 1 light chain 3B II (LC3B-II), which plays an essential role in the formation of autophagosome. Overexpression of HULC decreased, and its knockdown increased, LC3B-II expression after IR. Moreover, HULC can bind to Beclin-1 and increase its phosphorylation at threonine 119 [117]. This leads to dissociation of Beclin-1 from the complex with Bcl-2 protein and in turn results in activation of autophagy [165], explaining the mode of action of HULC in promoting autophagy [117].

Another lncRNA linked to autophagy is HOTAIR. HOTAIR promoted radiosensitivity of pancreatic cancer cells by increasing the levels of LC3-II. This indicated that HOTAIR can promote autophagosome formation. Moreover, HOTAIR enhanced expression of ATG7, a key protein involved in autophagosome formation that is responsible for vesicle progression [116]. In line with this, Guo et al. demonstrated that HOTAIR knockdown inhibited autophagy through suppression of the Wnt signaling pathway in radioresistant human cervical cancer HeLa cells [167].

5. ncRNAs Regulating Cell Cycle in Response to IR

In normal cells IR delays progression through the G1, S, and G2 phases of the cell cycle to allow for DNA repair and to prevent accumulation of harmful genomic lesions. The central regulator of cell cycle progression is p53, whose phosphorylation by ATM induces expression and phosphorylation of the cyclin-dependent kinase inhibitor p21. This leads to inhibition of CDK4/6-cyclin D and CDK1-cyclin B, causing cell cycle arrest in G1 and G2, respectively [168]. In addition, activation of signal transducers CHK1 and CHK2 by ATM and ATR promotes degradation of CDC25, leading to inhibition of CDK2-cyclin E and CDK1-cyclin B, which promotes cell cycle arrest in G1 and G2, respectively [169]. Effective induction of cell cycle arrest promotes radiosensitivity which means that the ability to progress through cell cycle after IR contributes to tumor radioresistance [170]. Several ncRNAs have been shown to play a role in cell cycle regulation after IR (Figure 4).
was identified as a target gene of let-7 and miR-16. Overexpression of let-7b resulted in cyclin D1 downregulation and sensitization of uveal melanoma cells to irradiation by increasing G1 arrest in vitro and in vivo [16]. Overexpression of miR-16 induced G0/G1 phase arrest and suppressed cell proliferation after IR resulting in enhanced radiosensitivity of prostate cancer cells [18]. MiR-375 abrogates the cell cycle G1 arrest through inactivation of the p53 pathway in gastric cancer cells [94]. Additionally, miR-300 desensitized lung cancer cells to IR by suppressing p53-dependent G2 cell cycle arrest [92]. Overexpression of miR-145 increased radiosensitivity of cervical cancer cells by promoting G1 to S transition, which was abrogated by overexpression of either PTEN or p21 [79]. Similar to miR-106b, miR-17-mediated PTEN inhibition promoted G2 to M progression and enhanced proliferation of NPC cells. The effect of miR-17 overexpression was mediated by AKT signaling, as shown by reversion upon treatment with an AKT inhibitor [79]. Inhibition of c-MYC by miR-449a resulted in IR-induced G2/M arrest in prostate cancer cells. This effect was mediated by abrogated control of Cdc2/Cyclin B1 signaling. Additionally, both overexpression of miR-449a and knockdown of c-MYC sensitized prostate cancer cells to IR and miR-449a also enhanced radiosensitivity in xenograft models [66].

5.1. miRNAs

Several miRNAs affect cell cycle arrest and as such play a role in radiosensitivity. Cyclin D1 was identified as a target gene of let-7 and miR-16. Overexpression of let-7b resulted in cyclin D1 downregulation and sensitization of uveal melanoma cells to irradiation by increasing G1 arrest in vitro and in vivo [16]. Overexpression of miR-16 induced G0/G1 phase arrest and suppressed cell proliferation after IR resulting in enhanced radiosensitivity of prostate cancer cells [18]. MiR-375 abrogates the cell cycle G1 arrest through inactivation of the p53 pathway in gastric cancer cells [94]. Additionally, miR-300 desensitized lung cancer cells to IR by suppressing p53-dependent G2 cell cycle arrest [92]. Overexpression of miR-145 increased radiosensitivity of cervical cancer cells by promoting G1 to S transition, which was abrogated by overexpression of either PTEN or p21 [79]. Similar to miR-106b, miR-17-mediated PTEN inhibition promoted G2 to M progression and enhanced proliferation of NPC cells. The effect of miR-17 overexpression was mediated by AKT signaling, as shown by reversion upon treatment with an AKT inhibitor [79]. Inhibition of c-MYC by miR-449a resulted in IR-induced G2/M arrest in prostate cancer cells. This effect was mediated by abrogated control of Cdc2/Cyclin B1 signaling. Additionally, both overexpression of miR-449a and knockdown of c-MYC sensitized prostate cancer cells to IR and miR-449a also enhanced radiosensitivity in xenograft models [66].

5.2. lncRNAs

HOTAIR was shown to regulate several aspects of cellular response to IR, amongst them cell cycle. In cervical cancer knockdown of HOTAIR induced G1 phase arrest and thereby increased radiosensitivity in vitro and in vivo. G1 arrest upon HOTAIR knockdown was reversed by p21 inhibition. These findings demonstrate that HOTAIR regulates cell cycle progression in response to IR by inhibiting p21. In line with these results, HOTAIR was negatively correlated with p21 levels in cancer tissues [113].
Two other lncRNAs were involved in cell cycle regulation in cervical cancer: MALAT1 and NEAT1. High levels of MALAT1 characterized radioresistant cases of cervical cancer, and IR induced MALAT1 expression in cervical cancer cell lines. Knockdown of MALAT1 enhanced radiosensitivity by inducing apoptosis and G2/M arrest [126]. NEAT1 was also more abundant in radioresistant cases of cervical cancer. Similarly to MALAT1, knockdown of NEAT1 enhanced radiosensitivity by inducing apoptosis and cell cycle arrest in G1 phase. Silencing of Cyclin D1 copied the effect of NEAT1 inhibition on radioresistance, cell cycle and apoptosis. On the other hand, Cyclin D1 overexpression or inhibition of miR-193b, which targets Cyclin D1, partially rescued the phenotype of NEAT1 inhibition. This showed that the effect of NEAT1 in response to IR is at least in part dependent on miR-193b and Cyclin D1. However, in vivo experiments demonstrated that although knockdown of NEAT1 reduced tumor volume and weight, combination with IR did not result in further reduction, and the observed effect was even worse than radiotherapy alone. This discrepancy between in vitro and in vivo models requires further clarification [127].

lncRNA UCA1 promoted radioresistance in colorectal and prostate cancer. UCA1 inhibition rendered prostate cancer cells more sensitive to IR and resulted in accumulation of cells in the G2/M phase. Mechanistically, UCA1 promoted phosphorylation of several kinases implicated in tumor radioresistance and cell cycle regulation: AKT, FAK, FGR, and AMPKα1 [136]. Unlike in prostate cancer, UCA1 inhibition in CRC cells attenuated the G2/M arrest induced by IR, while it promoted apoptosis and inhibited migration and EMT of CRC cells [171]. Thus, the mechanism underlying UCA1 effect on radioresistance involves cell cycle regulation in prostate cancer, but apparently not in CRC.

6. ncRNAs Modulating Glycolysis in IR-Response

Cancer cells exhibit increased energy demand to sustain their rapid proliferation and growth. The energy mostly derives from glycolysis, a process in which glucose is converted to pyruvate, providing energy and intermediates for other metabolic pathways. This preference of cancer cells for anaerobic glycolysis over oxidative phosphorylation is recognized as the Warburg effect [172]. Several glycolytic enzymes, e.g., HK2, LDHA, GLUT1, and PKM2 are upregulated in cancer cells [173]. Reprogramming of glucose metabolism in cancer cells is driven by HIF-1α and c-Myc [174]. Glycolysis has a major contribution to radioresistance of cancer cells, and targeting glycolytic enzymes has been shown to improve radiotherapy efficacy [175]. A number of ncRNAs are involved in determining radiosensitivity of cancer cells by regulating glycolysis (Figure 5).

Figure 5. ncRNAs regulating IR-induced glycolysis. ncRNAs promoting (green) or inhibiting (red) glycolysis.
6.1. miRNAs

Two miRNAs, miR-33a and miR-448, directly targeted HIF-1α to inhibit glycolysis and promote radiosensitivity of cancer cells. Overexpression of miR-33a enhanced radiosensitivity of melanoma cells in vitro and in vivo by inhibiting enzymes crucial for glycolysis: HIF-1α, HK1, HK2, and LDHA. Overexpression of HIF-1α, a previously identified miR-33a target [176], rescued the miR-33a-mediated inhibition of glycolysis [27]. A similar mechanism was reported for miR-448 in glioma cells. miR-448 directly targeted HIF-1α, which led to inhibition of proteins involved in glycolysis: HK1, HK2, LDHA [64].

miR-133b sensitized NSCLC cells to IR and negatively regulated glycolysis. This effect was mediated by targeting PKM2, an enzyme converting P-enolpyruvate to pyruvate. Overexpression of PKM2 rescued the effect of miR-133b on radiosensitivity and glycolysis [43]. Another miRNA that inhibited glycolysis, miR-449a, was shown to target LDHA, an enzyme which catalyzes the last step in glycolysis, conversion of pyruvate to lactate. miR-449a mimics promoted radiosensitivity of lung cancer cells, resulting in enhanced apoptosis and DNA damage, and reduced glycolysis rate. Silencing of LDHA copied the effect of miR-449 overexpression on cellular response to IR [65].

6.2. lncRNAs

In addition, a lncRNA and a circRNA have been implicated in regulating glycolysis in response to IR. Knockdown of lncRNA UCA1 enhanced radiosensitivity and reduced glycolysis rates in cervical cancer cell lines by decreasing levels of HK2, a key enzyme involved in the first step of glycolysis. Treatment with inhibitor of glycolysis reversed the positive effect of UCA1 overexpression on HK2 levels and radioresistance [137]. Silencing of circPITX1 promoted radiosensitivity of glioma cells in vitro and in vivo by inhibiting glycolysis. circPITX1 acted as a sponge for miR-329-3p to protect NEK2 from miRNA-mediated inhibition. The relevance of the circPITX1/miR-329-3p/NEK2 axis in radioresistance and glycolysis was confirmed by rescue experiments and inhibition of glycolysis [107]. Although not directly involved in glycolysis, NEK2 was previously shown to regulate splicing of pyruvate kinase M2 (PKM2), a key player in this pathway [177].

7. ncRNAs Affecting the Wnt/β-Catenin Pathway in Response to IR

The Wnt/β-catenin signaling is an example of an oncogenic pro-survival pathway hyperactivated in many types of cancer [178,179] and promotes reprogramming of cancer cell metabolism and cancer immunity [180]. Recently, the Wnt/β-catenin pathway has also been implicated in stimulating radioresistance of cancer cells by affecting cell cycle, apoptosis, DNA repair, and cell proliferation [181]. Several miRNAs and IncRNAs have also been implicated in the Wnt/β-catenin pathway (Figure 6).

Figure 6. ncRNAs involved in the IR-induced Wnt/β-catenin pathway. ncRNAs promoting (green) or inhibiting (red) the Wnt/β-catenin pathway-induced radioresistance.
7.1. miRNAs

miR-320 directly targeted β-catenin in cervical cancer cells. Both overexpression of miR-320 and knockdown of β-catenin promoted radiosensitivity of cervical cancer cells. In line with this, miRNA-320 levels were decreased and β-catenin levels increased in radioresistant cervical cancer cells compared to more sensitive parental cells [61].

Contradictory effects of miR-301a on Wnt/β-catenin signaling pathway and radiosensitivity were demonstrated. miR-301a was shown to directly target Wnt that activates and TCEAL7 that suppress β-catenin signaling [58,93]. Upregulation of miR-301a directly inhibited Wnt and indirectly β-catenin and cyclin D1 in ESCC cells and this led to increased radiosensitivity, reduced proliferation and migration of ESCC cells [58]. In contrast, miR-301a-mediated TCEAL7 inhibition increased transcriptional activity of β-catenin. Moreover, inhibition of miR-301a and overexpression of TCEAL7 reversed the radioresistant miR-301a phenotype in GMB cells in vitro and in vivo [93]. These opposite effects could be attributed to a cell-line specific miR-301a function.

miR-185-3p sensitized NPC cells to IR by targeting Wnt2B protein and an inverse relationship between expression levels of miR-185-3p and Wnt2B was confirmed in NPC cells and tissues [50]. Wnt2B is also targeted by miR-324-3p, whose overexpression increased radiosensitivity and impaired Wnt2B signaling after IR. Furthermore, miR-324-3p levels decreased and Wnt2B levels increased in NPC tissues after radiotherapy [62]. In addition, miR-1275 directly targeted Wnt1 in ESCC cells. Overexpression of miR-1275 enhanced radiosensitivity via inhibition of the epithelial to mesenchymal transition (EMT). Moreover, miR-1275 reduced tumor growth and promoted radiosensitivity in vivo [71].

7.2. lncRNAs

A handful of lncRNAs have been linked to IR response by regulating the Wnt/β-catenin pathway. lincRNA-p21 was downregulated in gastric cancer and CRC cells and tissues [99,100]. Ectopic overexpression of lincRNA-p21 enhanced radiosensitivity and inhibited the Wnt/β-catenin pathway in both tumor types. Levels of β-catenin and its target genes, c-MYC and Cyclin D1, were also downregulated upon lincRNA-p21 overexpression, as well as upon IR in CRC [100]. Inhibition of the β-catenin pathway abolished the effects of lincRNA-p21 overexpression on cell proliferation and radiosensitivity in gastric cancer cells [99]. This supports the role of lincRNA-p21 in promoting radiosensitivity by inhibiting the Wnt/β-catenin pathway.

In pancreatic ductal adenocarcinoma (PDAC) cells HOTAIR was induced by IR, while its knockdown enhanced radiosensitivity. Upon HOTAIR knockdown expression of Wnt inhibitory factor 1 (WIF-1) was increased and in line with that, levels of HOTAIR and WIF-1 were negatively correlated in clinical samples. Furthermore, overexpression of WIF-1 enhanced radiosensitivity of PDAC cells, copying the effect of HOTAIR knockdown [114]. Although the activity of Wnt/β-catenin pathway was not assessed in these experiments, the authors suggest that HOTAIR may be involved in IR response in PDAC cells by promoting this pathway.

WISP1 is a downstream target of Wnt/β-catenin pathway. It was upregulated in ESCC tissues and promoted radiosensitivity of ESCC cells in vitro and in vivo. Knockdown of IncRNA BOKAS, an IR-induced IncRNA, reduced expression of WISP1 upon IR [104]. However, it was not demonstrated whether BOKAS affects WISP1 via the Wnt/β-catenin pathway or if some other mechanism is involved.

8. Conclusions

Non-coding RNAs have emerged as key regulators in various processes in health and disease. In cancer, ncRNAs have been shown to contribute to carcinogenesis, differentiate between cancer subtypes, predict prognosis, and influence treatment outcome. Radiation is a treatment of choice for many cancer types. However, while some tumors are sensitive to radiotherapy, others demonstrate radioresistance. Therefore, mechanisms underlying tumor radioresistance and potential options of combination therapy to improve the outcome are being investigated. Here, we have summarized
the current knowledge on the role of ncRNAs in determining the radiosensitivity of various cancers. From this review, it is evident that miRNAs and lncRNAs are involved in many aspects of cellular response to radiation. While some promote tumor radiosensitivity, others render tumors more radioresistant. Expression levels of several of these ncRNAs are also affected by IR. One of the key players in IR response, p53, regulates the expression of several miRNAs (e.g., miR-34 [182]) and lncRNAs (e.g., Damage Induced Noncoding RNA (DINO) [183]), and can itself be regulated by ncRNAs [182,184]. Many ncRNAs have been associated with response to radiotherapy and can be used to predict efficacy of radiation treatment. Functional studies revealed different underlying mechanisms, involving crucial aspects of cellular response to IR, such as DNA damage repair, cell cycle control, apoptosis etc. Moreover, in vitro and in vivo studies demonstrated that modulation of the levels of ncRNAs can significantly enhance radiosensitivity of tumor cells. This indicates that ncRNAs may be used as targets to improve outcome of radiotherapy. The functional relevance was shown for multiple ncRNAs, indicating a great potential in combination radiotherapy. In recent years, several preclinical and clinical trials targeting ncRNAs, especially miRNAs, have been initiated. This further demonstrates the therapeutic potential of targeting RNA. With the development of advanced delivery strategies for RNA-based therapeutics, new combined radio-RNA therapies can emerge. Next to this, more studies are needed to identify ncRNAs serving as biomarkers of response to radiation in different cancer types. Further functional studies to determine underlying mechanisms of ncRNAs promoting radiosensitivity or radioresistance, as well as confirmation using in vivo models are also warranted.

**Funding:** This research was funded by the National Science Centre, Poland, grants number 2017/27/B/NZ1/00877 to AD-K and MP, 2015/19/B/ST7/02984 to SC and 2015/19/D/NZ1/03443 to IS-P.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Williams, J.R.; Zhang, Y.; Zhou, H.; Gridley, D.S.; Koch, C.J.; Russell, J.; Slater, J.S.; Little, J.B. A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. *Int. J. Radiat. Biol.* **2008**, *84*, 253–264. [CrossRef]
2. Li, G.; Liu, Y.; Liu, C.; Su, Z.; Ren, S.; Wang, Y.; Deng, T.; Huang, D.; Tian, Y.; Qiu, Y. Genome-wide analyses of long noncoding RNA expression profiles correlated with radioresistance in nasopharyngeal carcinoma via next-generation deep sequencing. *BMC Cancer* **2016**, *16*, 719. [CrossRef] [PubMed]
3. Zhou, J.; Cao, S.; Li, W.; Wei, D.; Wang, Z.; Li, G.; Pan, X.; Lei, D. Time-course differential lncRNA and mRNA expressions in radioresistant hypopharyngeal cancer cells. *Oncotarget* **2017**, *8*, 40994–41010. [CrossRef] [PubMed]
4. Yu, D.; Li, Y.; Ming, Z.; Wang, H.; Dong, Z.; Qiu, L.; Wang, T. Comprehensive circular RNA expression profile in radiation-treated HeLa cells and analysis of radioresistance-related circRNAs. *PeerJ* **2018**, *6*, e5011. [CrossRef] [PubMed]
5. Su, H.; Lin, F.; Deng, X.; Shen, L.; Fang, Y.; Fei, Z.; Zhao, L.; Zhang, X.; Pan, H.; Xie, D.; et al. Profiling and bioinformatics analyses reveal differential circular RNA expression in radioresistant esophageal cancer cells. *J. Transl. Med.* **2016**, *14*, 225. [CrossRef] [PubMed]
6. Chaudhry, M.A.; Sachdeva, H.; Omaruddin, R.A. Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways. *DNA Cell Biol.* **2010**, *29*, 553–561. [CrossRef]
7. Chaudhry, M.A.; Omaruddin, R.A.; Brumbaugh, C.D.; Tariq, M.A.; Pourmand, N. Identification of radiation-induced microRNA transcriptome by next-generation massively parallel sequencing. *J. Radiat. Res.* **2013**, *54*, 808–822. [CrossRef]
8. Fu, X.D. Non-coding RNA: A new frontier in regulatory biology. *Natl. Sci. Rev.* **2014**, *1*, 190–204. [CrossRef]
9. Jonas, S.; Izaurralde, E. Towards a molecular understanding of microRNA-mediated gene silencing. *Nat. Rev. Genet.* **2015**, *16*, 421–433. [CrossRef]
10. Baek, D.; Villen, J.; Shin, C.; Camargo, F.D.; Gygi, S.P.; Bartel, D.P.; Chi, N.C.; Shaw, R.M.; De Val, S.; Kang, G.; et al. Widespread changes in protein synthesis induced by microRNAs. *Nature* **2008**, *455*, 1710–1713. [CrossRef]
11. Fang, S.; Zhang, L.; Guo, J.; Niu, Y.; Wu, Y.; Li, H.; Zhao, L.; Li, X.; Teng, X.; Sun, X.; et al. NONCODEV5: A comprehensive annotation database for long non-coding RNAs. *Nucleic Acids Res.* 2018, 46, D308–D314. [CrossRef] [PubMed]

12. Chen, L.L.; Yang, L. Regulation of circRNA biogenesis. *RNA Biol.* 2015, 12, 381–388. [CrossRef] [PubMed]

13. Mercer, T.R.; Dinger, M.E.; Mattick, J.S. Long non-coding RNAs: Insights into functions. *Nat. Rev. Genet.* 2009, 10, 155–159. [CrossRef] [PubMed]

14. Ulitsky, I.; Bartel, D.P. XLincRNAs: Genomics, evolution, and mechanisms. *Cell* 2013, 154, 26–46. [CrossRef]

15. Wang, K.C.; Chang, H.Y. Molecular mechanisms of long noncoding RNAs. *Mol. Cell* 2011, 43, 904–914. [CrossRef]

16. Zhou, Y.; Zhang, L.; Fan, J.; Jia, R.; Song, X.; Xu, X.; Dai, L.; Zhuang, A.; Ge, S.; Fan, X. Let-7b overexpression leads to increased radiosensitivity of uveal melanoma cells. *Melanoma Res.* 2015, 25, 119–126. [CrossRef]

17. Sun, H.; Ding, C.; Zhang, H.; Gao, J. Let-7 miRNAs sensitize breast cancer stem cells to radiation-induced repression through inhibition of the cyclin D1/Akt1/Wnt1 signaling pathway. *Mol. Med. Rep.* 2016, 14, 3285–3292. [CrossRef]

18. Wang, F.; Mao, A.; Tang, J.; Zhang, Q.; Yan, J.; Wang, Y.; Di, C.; Gan, L.; Sun, C.; Zhang, H. microRNA-16-5p enhances radiosensitivity through modulating Cyclin D1/E1–pRb–E2F1 pathway in prostate cancer cells. *J. Cell. Physiol.* 2019, 234, 13182–13190. [CrossRef]

19. Song, L.; Lin, C.; Wu, Z.; Gao, J.; Zeng, Y.; Wu, J.; Li, M.; Li, J. MiR-18a impairs DNA damage response through downregulation of Ataxia telangiectasia mutated (ATM) kinase. *PLoS ONE* 2011, 6, e25454. [CrossRef]

20. Chen, X.; Wu, L.; Li, D.; Xu, Y.; Zhang, L.; Niu, K.; Kong, R.; Gu, J.; Xu, Z.; Chen, Z.; et al. Radiosensitizing effects of miR-18a-5p on lung cancer stem-like cells via downregulating both ATM and HIF-1α. *Cancer Med.* 2018, 7, 3834–3847. [CrossRef]

21. Zhang, X.; Li, Y.; Wang, D.; Wei, X. miR-22 suppresses tumorigenesis and improves radiosensitivity of breast cancer cells by targeting Sirt1. *Biol. Res.* 2017, 50. [CrossRef]

22. Wang, P.; Zhang, J.; Zhang, L.; Zhu, Z.; Fan, J.; Chen, L.; Zhuang, L.; Luo, J.; Chen, H.; Liu, L.; et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. *Gastroenterology* 2013, 145. [CrossRef]

23. Lal, A.; Pan, Y.; Navarro, F.; Dykxhoorn, D.M.; Moreau, L.; Meire, E.; Bentwich, Z.; Lieberman, J.; Chowdhury, D. MiR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. *Nat. Struct. Mol. Biol.* 2009, 16, 492–498. [CrossRef] [PubMed]

24. Guo, P.; Lan, J.; Ge, J.; Nie, Q.; Guo, L.; Qiu, Y.; Mao, Q. MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated (ATM) kinase. *PLoS ONE* 2011, 6, e25454. [CrossRef]

25. Meng, C.; Liu, Y.; Shen, Y.; Liu, S.; Wang, Z.; Ye, Q.; Liu, H.; Liu, X.; Jia, L. MicroRNA-26b suppresses autophagy in breast cancer cells by targeting DRAM1 mRNA, and is downregulated by irradiation. *Oncol. Lett.* 2018, 15, 1435–1440. [CrossRef] [PubMed]

26. Xu, C.G.; Yang, M.F.; Fan, J.X.; Wang, W. MiR-30a and miR-205 are downregulated in hypoxia and modulate radiosensitivity of prostate cancer cells by inhibiting autophagy via TP53INP1. *Eur. Rev. Med. Pharmacol. Sci.* 2016, 20, 1501–1508. [PubMed]

27. Cao, K.; Li, J.; Chen, J.; Qian, L.; Wang, A.; Chen, X.; Xiong, W.; Tang, J.; Tang, S.; Chen, Y.; et al. microRNA-33a-5p increases radiosensitivity by inhibiting glycolysis in melanoma. *Oncotarget* 2017, 8, 83660–83672. [CrossRef]

28. Duan, W.; Xu, Y.; Dong, Y.; Cao, L.; Tong, J.; Zhou, X. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. *J. Radiat. Res.* 2013, 54, 611–619. [CrossRef] [PubMed]

29. Cortez, M.A.; Valdecasas, D.; Niknam, S.; Pelletier, H.J.; Diao, L.; Giri, U.; Komaki, R.; Calin, G.A.; Gomez, D.R.; Chang, J.Y.; et al. In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation. *Mol. Ther. Nucleic Acids* 2015, 4, e270. [CrossRef]

30. Yin, H.; Ma, J.; Chen, L.; Piao, S.; Zhang, Y.; Zhang, S.; Ma, H.; Li, Y.; Qu, Y.; Wang, X.; et al. MiR-99a enhances the radiation sensitivity of non-small cell lung cancer by targeting mTOR. *Cell. Physiol. Biochem.* 2018, 46, 471–481. [CrossRef]
31. Ng, W.L.; Yan, D.; Zhang, X.; Mo, Y.Y.; Wang, Y. Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. *DNA Repair (Amst)* **2010**, *9*, 1170–1175. [CrossRef] [PubMed]

32. Yan, D.; Ng, W.L.; Zhang, X.; Wang, P.; Zhang, Z.; Mo, Y.Y.; Mao, H.; Hao, C.; Olson, J.J.; Curran, W.J.; et al. Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. *PLoS ONE* **2010**, *5*, e11397. [CrossRef] [PubMed]

33. Sun, Q.; Liu, T.; Zhang, T.; Du, S.; Xie, G.; Lin, X.; Chen, L.; Yuan, Y. MiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin1. *Mol. Med. Rep.* **2015**, *11*, 3330–3336. [CrossRef] [PubMed]

34. Neijenhuis, S.; Bajrami, I.; Miller, R.; Lord, C.J.; Ashworth, A. Identification of miRNA modulators to PARP inhibitor response. *DNA Repair (Amst)* **2013**, *12*, 394–402. [CrossRef] [PubMed]

35. Deng, X.; Ma, L.; Wu, M.; Zhang, G.; Jin, C.; Guo, Y.; Liu, R. MiR-124 radiosensitizes human glioma cells by targeting CDK4. *J. Neurooncol.* **2013**, *114*, 263–274. [CrossRef] [PubMed]

36. Zhang, Y.H.; Wang, Q.Q.; Li, H.; Ye, T.; Gao, F.; Liu, Y.C. miR-124 radiosensitizes human esophageal cancer cell TE-1 by targeting CDK4. *Genet. Mol. Res.* **2016**, *15*. [CrossRef]

37. Wang, M.; Meng, B.; Yu, J.; Chen, Q.; Liu, Y. MiR-124 inhibits growth and enhances radiation-induced apoptosis in non-small cell lung cancer by inhibiting STAT3. *Cell. Physiol. Biochem.* **2018**, *44*, 2017–2028. [CrossRef]

38. Fu, Y.; Xiong, J. MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3. *Croat. Med. J.* **2016**, *57*, 457–464. [CrossRef]

39. Gu, H.; Liu, M.; Ding, C.; Wang, X.; Wang, R.; Wu, X.; Fan, R. Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1. *Cancer Med.* **2016**, *5*, 1174–1182. [CrossRef]

40. Pedroza-Torres, A.; Campos-Parra, A.D.; Millan-Catalan, O.; Loissell-Baltazar, Y.A.; Zamudio-Meza, H.; De Leon, D.C.; Montalvo-Esquível, G.; Isla-Ortiz, D.; Herrera, L.A.; Ángeles-Zaragoza, O.; et al. MicroRNA-125 modulates radiosensitivity through targeting p21 in cervical cancer. *Oncol. Rep.* **2018**, *39*, 1532–1540. [CrossRef] [PubMed]

41. Metheetrairut, C.; Adams, B.D.; Nallur, S.; Weidhaas, J.B.; Slack, F.J. Cel-mir-237 and its homologue, hsa-mir-125b, modulate the cellular response to ionizing radiation. *Oncogene* **2017**, *36*, 512–524. [CrossRef]

42. Yang, Q.S.; Jiang, L.P.; He, C.Y.; Tong, Y.N.; Liu, Y.Y. Up-regulation of microRNA-133a inhibits the MEK/ERK signaling pathway to promote cell apoptosis and enhance radiosensitivity of cervical cancer cells by targeting E2F1. *Life Sci.* **2018**, *199*, 167–178. [CrossRef]

43. Liu, G.; Li, Y.; Gao, X. Overexpression of microRNA-133b sensitizes non-small cell lung cancer cells to irradiation through the inhibition of glycolysis. *Oncol. Lett.* **2016**, *11*, 2903–2908. [CrossRef]

44. Lu, H.J.; Jin, P.Y.; Tang, Y.; Fan, S.H.; Zhang, Z.F.; Wang, F.; Wu, D.M.; Lu, J.; Zheng, Y.L. microRNA-136 inhibits proliferation and promotes apoptosis and radiosensitivity of cervical carcinoma through the NF-κB pathway by targeting E2F1. *Life Sci.* **2018**, *199*, 2625–2634. [CrossRef]

45. Wang, Y.; Huang, J.W.; Li, M.; Cavenee, W.K.; Mitchell, P.S.; Zhou, X.; Tewari, M.; Furnari, F.B.; Taniguchi, T. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. *Mol. Cancer Res.* **2011**, *9*, 1100–1111. [CrossRef]

46. Wu, S.J.; Chen, J.; Wu, B.; Wang, Y.J.; Guo, K.Y. MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma. *J. Exp. Clin. Cancer Res.* **2018**, *37*, 18. [CrossRef]

47. Sun, D.; Mu, Y.; Piao, H. MicroRNA-153-5p sensitizes human glioma cells to radiation by targeting BCL2 in human glioma. *Biol. Res.* **2018**, *51*, 56. [CrossRef]

48. Gasparini, P.; Lovat, F.; Fassan, M.; Casadei, L.; Cascione, L.; Jacob, N.K.; Carasi, S.; Palmieri, D.; Costinean, S.; Shapiro, C.L.; et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 4536–4541. [CrossRef]

49. Moskwa, P.; Buffa, F.M.; Pan, Y.; Panchakshari, R.; Gottipati, P.; Muschel, R.J.; Beech, J.; Kulshrestha, R.; Abdelmohsen, K.; Weinstock, D.M.; et al. MiR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. *Mol. Cell* **2011**, *41*, 210–220. [CrossRef]
50. Li, G.; Wang, Y.; Liu, Y.; Su, Z.; Liu, C.; Ren, S.; Deng, T.; Huang, D.; Tian, Y.; Qiu, Y. miR-185-3p regulates nasopharyngeal carcinoma radioresistance by targeting WNT2B in vitro. *Cancer Sci.* **2014**, *105*, 1560–1568. [CrossRef]

51. Kwon, J.E.; Kim, B.Y.; Kwak, S.Y.; Bae, I.H.; Han, Y.H. Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. *Apoptosis* **2013**, *18*, 896–909. [CrossRef]

52. Yi, H.; Liang, B.; Jia, J.; Liang, N.; Xu, H.; Ju, G.; Ma, S.; Liu, X. Differential roles of miR-199a-5p in radiation-induced autophagy in breast cancer cells. *FEBS Lett.* **2013**, *587*, 436–443. [CrossRef]

53. Sun, Q.; Liu, T.; Yuan, Y.; Guo, Z.; Xie, G.; Du, S.; Lin, X.; Xu, Z.; Liu, M.; Wang, W.; et al. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. *Int. J. Cancer* **2015**, *136*, 1003–1012. [CrossRef]

54. Liu, H.Y.; Zhang, Y.Y.; Zhu, B.L.; Feng, F.Z.; Zhang, H.T.; Yan, H.; Zhou, B. MiR-203a-3p regulates biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM. *J. Ovarian Res.* **2019**, *12*. [CrossRef]

55. Hu, J.L.; He, G.Y.; Lan, X.L.; Zeng, Z.C.; Guan, J.; Ding, Y.; Qian, X.L.; Liao, W.T.; Ding, Y.Q.; Liang, L. Inhibition of ATG12-mediated autophagy by miR-214 enhances radiosensitivity in colorectal cancer. *Oncogenesis* **2018**, *7*, 16. [CrossRef]

56. Zhang, X.; Shi, H.; Lin, S.; Ba, M.; Cui, S. MicroRNA-216a enhances the radiosensitivity of pancreatic cancer cells by inhibiting beclin-1-mediated autophagy. *Oncol. Rep.* **2015**, *34*, 1557–1564. [CrossRef]

57. Liang, L.; Zhaorisky, N.G.; Deng, Y.; Wu, X.; Liu, Y.; Liu, F.; Cai, G.; Gu, W.; Shen, L.; et al. MicroRNA-223 enhances radiation sensitivity of U87MG cells in vitro and in vivo by targeting ataxia telangiectasia mutated. *Int. J. Radiat. Oncol. Biol. Phys.* **2014**, *88*, 955–960. [CrossRef]

58. Su, H.; Wu, Y.; Fang, Y.; Shen, L.; Fei, Z.; Xie, C.; Chen, M. MicroRNA-301a targets WNT1 to suppress cell proliferation and migration and enhance radiosensitivity in esophageal cancer cells. *Oncol. Rep.* **2019**, *41*, 599–607. [CrossRef]

59. Liang, Z.; Ahn, J.; Guo, D.; Votaw, J.R.; Shim, H. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. *Pharm. Res.* **2013**, *30*, 1008–1016. [CrossRef]

60. Lv, Q.; Hu, J.X.; Li, Y.J.; Xie, N.; Song, D.D.; Zhao, W.; Yan, Y.F.; Li, B.S.; Wang, P.Y.; Xie, S.Y. MiR-320a effectively suppresses lung adenocarcinoma cell proliferation and metastasis by regulating STAT3 signals. *Cancer Sci.* **2017**, *18*, 142–151. [CrossRef]

61. Yang, C.X.; Zhang, S.M.; Li, J.; Yang, B.; Ouyang, W.; Mei, Z.J.; Chen, J.; Dai, J.; Ke, S.; Zhou, F.X.; et al. The effect of glycolysis inhibition by miR-448 on glioma radiosensitivity. *Int. J. Radiation Oncol. Biol. Phys.* **2013**, *85*, 241–248. [CrossRef]

62. Li, G.; Liu, Y.; Su, Z.; Ren, S.; Zhu, G.; Tian, Y.; Qiu, Y. MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by directly targeting WNT2B. *Eur. J. Cancer* **2013**, *49*, 2596–2607. [CrossRef] [PubMed]

63. Mansour, W.Y.; Bogdanova, N.V.; Kasten-Pisula, U.; Rieckmann, T.; Köcher, S.; Borgmann, K.; Baumann, M.; Krause, M.; Petersen, C.; Hu, H.; et al. Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma. *Radiother. Oncol.* **2013**, *106*, 147–154. [CrossRef] [PubMed]

64. Lan, F.; Qin, Q.; Yu, H.; Yue, X. Effect of glycolysis inhibition by miR-448 on glioma radiosensitivity. *J. Neurosurg.* **2020**, *132*, 1456–1464. [CrossRef] [PubMed]

65. Li, L.; Liu, H.; Du, L.; Xi, P.; Wang, Q.; Li, Y.; Liu, D. MiR-449a suppresses LDHA-mediated glycolysis to enhance the sensitivity of non-small cell lung cancer cells to ionizing radiation. *Oncol. Res.* **2018**, *26*, 547–556. [CrossRef]

66. Mao, A.; Zhao, Q.; Zhou, X.; Sun, C.; Si, J.; Zhou, R.; Gan, L.; Zhang, H. MicroRNA-449a enhances radiosensitivity by downregulation of e-MyC in prostate cancer cells. *Sci. Rep.* **2016**, *6*, 27346. [CrossRef] [PubMed]

67. Chen, H.; Yao, X.; Di, X.; Zhang, Y.; Zhu, H.; Liu, S.; Chen, T.; Yu, D.; Sun, X. MiR-450a-5p inhibits autophagy and enhances radiosensitivity by targeting dual-specificity phosphatase 10 in esophageal squamous cell carcinoma. *Cancer Lett.* **2020**, *483*, 114–126. [CrossRef]

68. Yang, B.; Kuai, F.; Chen, Z.; Fu, D.; Liu, J.; Wu, Y.; Zhong, J. MiR-634 decreases the radioresistance of human breast cancer cells by targeting STAT3. *Cancer Biother. Radiopharm.* **2020**, *35*, 241–248. [CrossRef]

69. Lee, H.C.; Her, N.-G.; Kang, D.; Jung, S.H.; Shin, J.; Lee, M.; Bae, I.H.; Kim, Y.-N.; Park, H.J.; Ko, Y.-G.; et al. Radiation-inducible miR-770-5p sensitizes tumors to radiation through direct targeting of PDZ-binding kinase. *Cell Death Dis.* **2017**, *8*, e2693. [CrossRef]
70. El Bezawy, R.; Cominetti, D.; Fenderico, N.; Zuco, V.; Beretta, G.L.; Dugo, M.; Arrighetti, N.; Stucchi, C.; Rancati, T.; Valdagni, R.; et al. miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. *Cancer Lett.* **2017**, *395*, 53–62. [CrossRef]

71. Xie, C.; Wu, Y.; Fei, Z.; Fang, Y.; Xiao, S.; Su, H. MicroRNA-1275 induces radiosensitization in oesophageal cancer by regulating epithelial-to-mesenchymal transition via Wnt/β-catenin pathway. *J. Cell. Mol. Med.* **2020**, *24*, 747–759. [CrossRef] [PubMed]

72. Wu, S.Y.; Lin, K.C.; Chiou, J.F.; Jeng, S.C.; Cheng, W.H.; Chang, C.L.; Lin, W.C.; Wu, L.L.; Lee, H.L.; Chen, R.J. MicroRNA-17-5p post-transcriptionally regulates p21 expression in irradiated betel quid chewing-related oral squamous cell carcinoma cells. *Strahlenther. Onkol.* **2013**, *189*, 675–683. [CrossRef]

73. Hu, Z.; Zhou, S.; Luo, H.; Ji, M.; Zheng, J.; Huang, F.; Wang, F. miRNA-17 promotes nasopharyngeal carcinoma radioresistance by targeting PTEN/AKT. *Int. J. Clin. Exp. Pathol.* **2019**, *12*, 229–240. [PubMed]

74. Zhang, Y.; Zheng, L.; Ding, Y.; Li, Q.; Wang, R.; Liu, T.; Sun, Q.; Yang, H.; Peng, S.; Wang, W.; et al. MIR-20a induces cell radioresistance by activating the PTEN/PI3K/Akt signaling pathway in hepatocellular carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* **2015**, *92*, 1132–1140. [CrossRef]

75. Zhou, L.; Bai, H.; Deng, C.; Wang, C.; Xu, R.; Shao, S. MicroRNA-21 is involved in X-ray irradiation resistance in K562 leukemia cells. *Hematology* **2015**, *20*, 343–348. [CrossRef] [PubMed]

76. Liu, Z.L.; Wang, H.; Liu, J.; Wang, Z.X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. *Mol. Cell. Biochem.* **2013**, *372*, 37–45. [CrossRef]

77. Wang, J.; Xu, J.; Fu, J.; Yuan, D.; Guo, F.; Zhou, C.; Shao, C. MiR-29a regulates radiosensitivity in human intestinal cells by targeting PTEN gene. *Radiat. Res.* **2016**, *186*, 292–301. [CrossRef]

78. Vahabi, M.; Pulito, C.; Sacconi, A.; Donzelli, S.; D’Andrea, M.; Manciocco, V.; Pallini, R.; Paci, P.; Sanguineti, G.; Strigari, L.; et al. MiR-96-5p targets PTEN expression and determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. *Cell Cycle* **2015**, *14*, 38, 141. [CrossRef]

79. Zheng, L.; Zhang, Y.; Liu, Y.; Zhou, M.; Lu, Y.; Yuan, L.; Zhang, C.; Hong, M.; Wang, S.; Li, X. MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. *J. Transl. Med.* **2015**, *13*, 252. [CrossRef]

80. Xiao, S.; Yang, Z.; Lv, R.; Zhao, J.; Wu, M.; Liao, Y.; Liu, Q. miR-135b contributes to the radioresistance by targeting glycogen synthase kinase-3 in human nasopharyngeal carcinoma cells. *PloS ONE* **2014**, *9*, e108810. [CrossRef]

81. Huang, Y.; Tan, D.; Xiao, J.; Li, Q.; Zhang, X.; Luo, Z. MIR-150 contributes to the radioresistance in nasopharyngeal carcinoma by targeting epithelial-to-mesenchymal transition via Wnt/β-catenin pathway. *Int. J. Clin. Exp. Pathol.* **2013**, *6*, 111–118. [CrossRef]

82. Yang, F.; Liu, Q.; Hu, C.-M. Epstein-Barr virus-encoded LMP1 increases miR-155 expression, which promotes radioresistance of nasopharyngeal carcinoma via suppressing UBQLN1. *Eur. Rev. Med. Pharmacol. Sci.* **2015**, *19*, 4507–4515. [PubMed]

83. Qu, C.; Liang, Z.; Huang, J.L.; Zhao, R.; Su, C.; Wang, S.; Wang, X.; Zhang, R.; Lee, M.H.; Yang, H. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. *Cell Cycle* **2012**, *11*, 785–796. [CrossRef] [PubMed]

84. Tang, Y.; Cui, Y.; Li, Z.; Jiao, Z.; Zhang, Y.; He, Y.; Chen, G.; Zhou, Q.; Wang, W.; Zhou, X.; et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. *J. Exp. Clin. Cancer Res.* **2016**, *35*, 7. [CrossRef]

85. Yang, W.; Sun, T.; Cao, J.; Liu, F.; Tian, Y.; Zhu, W. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. *Exp. Cell Res.* **2012**, *318*, 944–954. [CrossRef]

86. He, X.; Fan, S. Ihsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1. *Oncl. Rep.* **2018**, *39*, 977–984. [CrossRef]

87. Zhang, Q.; Zhang, S. MIR-214 promotes radioresistance in Human ovarian cancer cells by targeting PETN. *Biosci. Rep.* **2017**, *37*. [CrossRef]

88. Xue, Q.; Sun, K.; Deng, H.J.; Lei, S.T.; Dong, J.Q.; Li, G.X. Anti-miRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN. *World J. Gastroenterol.* **2013**, *19*, 9307–9317. [CrossRef]

89. Li, G.; Deng, Y.; Wu, Y.; Liang, L.; Zhang, Z. The role of MiR-221 in regulating gastric cancer radiation sensitivity. *Int. J. Radiat. Oncol.* **2016**, *96*, E168. [CrossRef]
90. Zhang, C.; Kang, C.; Wang, P.; Cao, Y.; Lv, Z.; Yu, S.; Wang, G.; Zhang, A.; Jia, Z.; Han, L.; et al. MICRNA-221 and -222 regulate radiation sensitivity by targeting the PTEN pathway. *Int. J. Radiat. Oncol. Biol. Phys.* 2011, 80, 240–248. [CrossRef]

91. Zhang, C.-z.; Han, L.; Zhang, A.-l.; Fu, Y.-c.; Yue, X.; Wang, G.-x.; Jia, Z.-f.; Pu, P.-y.; Zhang, Q.-y.; Kang, C.-s. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. *BMC Cancer* 2010, 10. [CrossRef]

92. He, J.; Feng, X.; Hua, J.; Wei, L.; Lu, Z.; Wei, W.; Cai, H.; Wang, B.; Shi, W.; Ding, N.; et al. miR-300 regulates cellular radioresistance through targeting p53 and apafl in human lung cancer cells. *Cell Cycle* 2017, 16, 1943–1953. [CrossRef]

93. Yue, X.; Lan, F.; Xia, T. Hypoxic glioma cell-secreted exosomal miR-301a activates Wnt/β-catenin signaling and promotes radiation resistance by targeting TCEAL7. *Mol. Ther.* 2019, 27, 1939–1949. [CrossRef]

94. Liu, Y.; Xing, R.; Zhang, X.; Dong, W.; Zhang, J.; Yan, Z.; Li, W.; Cui, J.; Lu, Y. MiR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells. *DNA Repair (Amst)* 2013, 12, 741–750. [CrossRef]

95. Duan, X.M.; Liu, X.N.; Li, Y.X.; Cao, Y.Q.; Silayiding, A.; Zhang, R.K.; Wang, J.P. MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN. *Kaohsiung J. Med. Sci.* 2019, 35, 659–671. [CrossRef]

96. Ma, W.; Yu, J.; Qi, X.; Liang, L.; Zhang, Y.; Ding, Y.; Lin, X.; Li, G.; Ding, Y. Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb. *Oncotarget* 2015, 6, 15984–15994. [CrossRef]

97. Fan, L.; Wang, J.; Cao, Q.; Ding, X.; Li, B. Aberrant miR-1246 expression promotes radioresistance in non-small cell lung cancer: A potential prognostic biomarker and radiotherapy sensitization target. *Am. J. Cancer Res.* 2020, 10, 314–335.

98. Chen, G.; Li, Y.; He, Y.; Zeng, B.; Yi, C.; Wang, C.; Zhang, X.; Zhao, W.; Yu, D. Upregulation of circular RNA circATRN1L1 to sensitize oral squamous carcinomacell to irradiation. *Mol. Ther. Nucleic Acids* 2020, 19, 961–973. [CrossRef]

99. Chen, L.; Yuan, D.; Yang, Y.; Ren, M. LincRNA-p21 enhances the sensitivity of radiotherapy for gastric cancer by targeting the beta-catenin signaling pathway. *J. Cell Biochem.* 2019, 120, 6178–6187. [CrossRef]

100. Wang, G.; Li, Z.; Zhao, Q.; Zhu, Y.; Zhao, C.; Li, X.; Ma, Z.; Li, X.; Zhang, Y. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/beta-catenin signaling pathway. *Oncol Rep.* 2014, 31, 1839–1845. [CrossRef]

101. Liu, Y.; Yue, P.; Zhou, T.; Zhang, F.; Wang, H.; Chen, X. LncRNA MEG3 enhances (131)I sensitivity in thyroid carcinoma via sponging miR-182. *Biomed. Pharmacother.* 2018, 105, 1232–1239. [CrossRef]

102. Wang, Y.; Wang, C.; Chen, C.; Wu, F.; Shen, P.; Zhang, P.; He, G.; Li, X. Long non-coding RNA NEAT1 regulates epithelial membrane protein 2 expression to repress nasopharyngeal carcinoma migration and irradiation-resistance through miR-101-3p as a competing endogenous RNA mechanism. *Oncotarget* 2017, 8, 70156–70171. [CrossRef]

103. Zou, Y.; Yao, S.; Chen, X.; Liu, D.; Wang, J.; Yuan, X.; Rao, J.; Xiong, H.; Yu, S.; Yuan, X.; et al. LncRNA OIP5-AS1 regulates radioresistance by targeting DRYRK1A through miR-369-3p in colorectal cancer cells. *Eur. J. Cell Biol.* 2018, 97, 369–378. [CrossRef]

104. Zhang, H.; Luo, H.; Hu, Z.; Peng, J.; Jiang, Z.; Song, T.; Wu, B.; Yue, J.; Zhou, R.; Xie, R.; et al. Targeting WISP1 to sensitize esophageal squamous cell carcinoma to irradiation. *Oncotarget* 2015, 6, 6218–6234. [CrossRef]

105. Gou, C.; Han, P.; Li, J.; Gao, L.; Ji, X.; Dong, F.; Su, Q.; Zhang, Y.; Liu, X. Knockdown of lncRNA BLACAT1 enhances radiosensitivity of head and neck squamous cell carcinoma cells by regulating PSEN1. *Br. J. Radiol.* 2020, 93, 20190154. [CrossRef]

106. Lai, Y.; Chen, Y.; Lin, Y.; Ye, L. Down-regulation of LncRNA CCAT1 enhances radiosensitivity via regulating miR-148b in breast cancer. *Cell Biol. Int.* 2018, 42, 227–236. [CrossRef]

107. Guan, Y.; Cao, Z.; Du, J.; Liu, T.; Wang, T. Circular RNA circPITX1 knockdown inhibits glycolysis to enhance radiosensitivity of glioma cells by miR-329-3p/NEK2 axis. *Cancer Cell Int.* 2020, 20. [CrossRef]

108. Liu, Y.; Yao, K.; Zhang, K.; Wang, J.; Dai, Q.; Wang, R. Circular RNA PTK2 modifies the progression and radiosensitivity in gastric cancer via miR-369-3p/ZEB1 axis. *RSC Adv.* 2020, 10, 1711–1723. [CrossRef]
Cancers 2020, 12, 1662

109. Zhang, M.; Gao, C.; Yang, Y.; Li, G.; Dong, J.; Ai, Y.; Chen, N.; Li, W. Long noncoding RNA CRNDE/PRC2 participated in the radiotherapy resistance of human lung adenocarcinoma through targeting p21 expression. *Oncol. Res.* 2018, 26, 1245–1255. [CrossRef]

110. Zhang, J.; Li, W. Long noncoding RNA CYTOR sponges miR-195 to modulate proliferation, migration, invasion and radiosensitivity in non-small cell lung cancer cells. *Biosci. Rep.* 2018, 38. [CrossRef]

111. Zhang, H.; Hua, Y.; Jiang, Z.; Yue, J.; Shi, M.; Zhen, X.; Zhang, X.; Yang, L.; Zhou, R.; Wu, S. Cancer-associated fibroblast-promoted lncRNA DNM3OS confers radioresistance by regulating DNA damage response in esophageal squamous cell carcinoma. *Clin. Cancer Res.* 2019, 25, 1989–2000. [CrossRef]

112. Dou, Q.; Xu, Y.; Zhu, Y.; Hu, Y.; Yan, Y.; Yan, H. LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein. *Eur. J. Pharmacol.* 2019, 852, 134–141. [CrossRef]

113. Jiang, Y.; Li, Z.; Zheng, S.; Chen, H.; Zhao, X.; Gao, W.; Bi, Z.; You, K.; Wang, Y.; Li, W.; et al. The long non-coding RNA HOTAIR promotes tumorigenesis and radioresistance in breast cancer by sponging miR-324-3p and inducing ACK1 expression. *Mol. Ther. Nucleic Acids* 2019, 18, 871–881. [CrossRef]

114. Zhang, H.; Hua, Y.; Jiang, Z.; Yue, J.; Shi, M.; Zhen, X.; Zhang, X.; Yang, L.; Zhou, R.; Wu, S. Cancer-associated fibroblast-promoted lncRNA DNM3OS confers radioresistance by regulating DNA damage response in esophageal squamous cell carcinoma. *Clin. Cancer Res.* 2019, 25, 1989–2000. [CrossRef]

115. Hu, X.; Ding, D.; Zhang, J.; Cui, J. Knockdown of lncRNA HOTAIR sensitizes breast cancer cells to ionizing radiation through activating miR-218. *Biosci. Rep.* 2019, 39. [CrossRef]

116. Wu, C.; Yang, L.; Qi, X.; Wang, T.; Li, M.; Xu, K. Inhibition of long non-coding RNA CYTOR enhances radiosensitivity via regulating autophagy in pancreatic cancer. *Cancer Manag. Res.* 2018, 10, 5261–5271. [CrossRef]

117. Chen, C.; Wang, K.; Wang, Q.; Wang, X. LncRNA HULC mediates radioresistance via autophagy in prostate cancer cells. *Braz. J. Med. Biol. Res.* 2018, 51, e7080. [CrossRef]

118. Zhang, N.; Zeng, X.; Wu, C.; Yang, L.; Qi, X.; Wang, T.; Li, M.; Xu, K. Inhibition of long non-coding RNA CYTOR enhances radiosensitivity via regulating autophagy in pancreatic cancer. *Cancer Manag. Res.* 2018, 10, 5261–5271. [CrossRef]

119. Wang, B.; Zheng, J.; Li, R.; Tian, Y.; Lin, J.; Liang, Y.; Sun, Q.; Xu, A.; Zheng, R.; Liu, M.; et al. Long noncoding RNA LINC00963 promotes tumorigenesis and radioresistance in breast cancer by sponging miR-324-3p and inducing ACK1 expression. *Mol. Ther. Nucleic Acids* 2019, 18, 871–881. [CrossRef]

120. Shen, Y.; Liu, Y.; Sun, T.; Yang, W. LncRNA-p21 knockdown enhances radiosensitivity of hypoxic tumor cells by reducing autophagy through HIF-1/Akt/mTOR/P70S6K pathway. *Exp. Cell Res.* 2017, 358, 188–198. [CrossRef]

121. Yang, P.; Yang, Y.; An, W.; Xu, J.; Zhang, G.; Jie, J.; Zhang, Q. The long noncoding RNA-ROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR-145 pathway. *J. Gastroenterol. Hepatol.* 2017, 32, 837–845. [CrossRef]

122. Wang, X.; Liu, H.; Shi, L.; Yu, X.; Gu, Y.; Sun, X. LINP1 facilitates DNA damage repair through non-homologous end joining (NHEJ) pathway and subsequently decreases the sensitivity of cervical cancer cells to ionizing radiation. *Cell Cycle* 2018, 17, 439–447. [CrossRef]

123. Li, Z.; Zhou, Y.; Tu, B.; Bu, Y.; Liu, A.; Kong, J. Long noncoding RNA MALAT1 affects the efficacy of radiotherapy for esophageal squamous cell carcinoma by regulating Cks1 expression. *J. Oral Pathol. Med.* 2017, 46, 583–590. [CrossRef]

124. Jin, C.; Yan, B.; Lu, Q.; Lin, Y.; Ma, L. The role of MALAT1/miR-1/Slug axis on radioresistance in nasopharyngeal carcinoma. *Tumour Biol.* 2016, 37, 4025–4033. [CrossRef]

125. Lu, H.; He, Y.; Lin, L.; Qi, Z.; Ma, L.; Li, L.; Su, Y. Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145. *Tumour Biol.* 2016, 37, 1683–1691. [CrossRef] [PubMed]

126. Lu, Y.; Li, T.; Wei, G.; Liu, L.; Chen, Q.; Xu, L.; Zhang, K.; Zeng, D.; Liao, R. The long non-coding RNA NEAT1 regulates epithelial to mesenchymal transition and radioresistance in through miR-204/ZEB1 axis in nasopharyngeal carcinoma. *Tumour Biol.* 2016, 37, 11733–11741. [CrossRef] [PubMed]

127. Han, D.; Wang, J.; Cheng, G. LncRNA NEAT1 enhances the radio-resistance of cervical cancer via miR-193b-3p/CCND1 axis. *Oncotarget* 2018, 9, 2395–2409. [CrossRef]

128. Shi, R.; Wu, P.; Liu, M.; Chen, B.; Cong, L. Knockdown of lncRNA PCAT6 enhances radiosensitivity in triple-negative breast cancer cells by regulating miR-185-5p/TPD52 axis. *Onco Targets Ther.* 2020, 13, 3025–3037. [CrossRef]
129. Liu, J.; Sun, X.; Zhu, H.; Qin, Q.; Yang, X.; Sun, X. Long noncoding RNA POU6F2-AS2 is associated with oesophageal squamous cell carcinoma. *J. Biochem*. 2016, **160**, 195–204. [CrossRef]

130. Wu, D.; Li, Y.; Zhang, H.; Hu, X. Knockdown of IncRNA PVT1 enhances radiosensitivity in non-small cell lung cancer by sponging Mir-195. *Cell. Physiol. Biochem*. 2017, **42**, 2453–2466. [CrossRef]

131. He, Y.; Jing, Y.; Wei, F.; Tang, Y.; Yang, L.; Luo, J.; Yang, P.; Ni, Q.; Pang, J.; Liao, Q.; et al. Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. *Cell Death Dis.* 2018, **9**, 235. [CrossRef]

132. Wang, Y.; Chen, W.; Liu, J.; Zhang, H.; Yu, B.; Zhang, M.; Wei, F.; Wu, J.; Jiang, J.; Jia, Y.; et al. The IncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1alpha. *Cell Death Differ*. 2020, **27**, 695–710. [CrossRef] [PubMed]

133. Yu, Z.; Wang, G.; Zhang, C.; Liu, Y.; Chen, W.; Wang, H.; Liu, H. LncRNA SBF2-AS1 affects the radiosensitivity of non-small cell lung cancer via modulating microRNA-302a/MBNL3 axis. *Cell Cycle* 2019, **19**, 300–316. [CrossRef]

134. Song, W.; Zhang, J.; Xia, Q.; Sun, M. Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway. *Cell Cycle* 2019, **18**, 3177–3188. [CrossRef]

135. Jiang, H.; Hu, X.; Zhang, H.; Li, W. Down-regulation of LncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGBI1 expression. *Radiat. Oncol.* 2017, **12**, 65. [CrossRef]

136. Fotouhi Ghiam, A.; Taeb, S.; Huang, X.; Huang, V.; Ray, J.; Scarcello, S.; Hoey, C.; Jahangiri, S.; Fokas, E.; Loblaw, A.; et al. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. *Oncotarget* 2017, **8**, 4668–4689. [CrossRef]

137. Fan, L.; Huang, C.; Li, J.; Gao, T.; Lin, Z.; Yao, T. Long non-coding RNA urothelial cancer associated 1 regulates radioresistance via the hexokinase 2/glycolytic pathway in cervical cancer. *Int. J. Mol. Med.* 2018, **42**, 1875–1884. [CrossRef] [PubMed]

138. Kakarougkas, A.; Jeggo, P.A. DNA DSB repair pathway choice: An orchestrated handover mechanism. *Br. J. Radiol.* 2014, **87**, 20130685. [CrossRef]

139. Davis, A.J.; Chen, D.J. DNA double strand break repair via non-homologous end-joining. *Transl. Cancer Res.* 2013, **2**, 130–143. [CrossRef]

140. Wright, W.D.; Shah, S.S.; Heyer, W.D. Homologous recombination and the repair of DNA double-strand breaks. *J. Biol. Chem.* 2018, **293**, 10524–10535. [CrossRef]

141. Thapar, R. Regulation of DNA double-strand break repair by non-coding RNAs. *Molecules* 2018, **23**, 2789. [CrossRef] [PubMed]

142. Bekker-Jensen, S.; Mailand, N. Assembly and function of DNA double-strand break repair foci in mammalian cells. *DNA Repair (Amst)* 2010, **9**, 1219–1228. [CrossRef] [PubMed]

143. Zhou, L.; Yuan, R.; Serggio, L. Molecular mechanisms of irradiation-induced apoptosis. *Front. Biosci.* 2003, **8**, d9–d419. [CrossRef] [PubMed]

144. Sladky, V.; Schuler, F.; Fava, L.L.; Villunger, A. The resurrection of the PIDDosome—Emerging roles in the DNA-damage response and centrosome surveillance. *J. Cell Sci.* 2017, **130**, 3779–3787. [CrossRef] [PubMed]

145. Ray, P.; Guha, D.; Chakraborty, J.; Banerjee, S.; Adhikary, A.; Chakraborty, S.; Das, T.; Sa, G. Crocetin exploits p53-induced death domain (PIDD) and FAS-associated death domain (FADD) proteins to induce apoptosis in colorectal cancer. *Sci. Rep.* 2016, **6**, 32979. [CrossRef]

146. Pistritto, G.; Trisciuoglio, D.; Ceci, C.; Garufi, A.; D’Orazi, G. Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. *Aging (Albany NY)* 2016, **8**, 603–619. [CrossRef]

147. Villanova, L.; Careccia, S.; De Maria, R.; Fiori, M.E. Micro-economics of apoptosis in cancer: ncRNAs modulation of BCL-2 family members. *Int. J. Mol. Sci.* 2018, **19**, 958. [CrossRef]

148. Rossi, M.N.; Antonangeli, F. LncRNAs: New players in apoptosis control. *Int. J. Cell Biol.* 2014, **2014**, 473857. [CrossRef]

149. Borras-Fresneda, M.; Barquinero, J.F.; Gomolka, M.; Hornhardt, S.;RSS; Hill, J.; Barrios, L. Differences in DNA repair capacity, cell death and transcriptional response after irradiation between a radiosensitive and a radioresistant cell line. *Sci. Rep.* 2016, **6**, 27043. [CrossRef]

150. Slack, F.J.; Chinnaiyan, A.M. The role of non-coding RNAs in oncology. *Cell* 2019, **179**, 1033–1055. [CrossRef]

151. Vousden, K.H.; Prives, C. Blinded by the light: The growing complexity of p53. *Cell* 2009, **137**, 413–431. [CrossRef] [PubMed]
Cancers 2020, 12, 1662

152. Indovina, P.; Pentimalli, F.; Casini, N.; Vocca, I.; Giordano, A. RBI dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy. *Oncotarget* 2015, 6, 17873–17890. [CrossRef] [PubMed]

153. Knezevic, D.; Brash, D.E. Role of E2F1 in apoptosis: A case study in feedback loops. *Cell Cycle* 2004, 3, 729–732. [CrossRef] [PubMed]

154. Xu, N.; Lao, Y.; Zhang, Y.; Gillespie, D.A. Akt: A double-edged sword in cell proliferation and genome stability. *J. Oncol.* 2012, 951724. [CrossRef] [PubMed]

155. Fresno Vara, J.A.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; Gonzalez-Baron, M. PI3K/Akt signalling pathway and cancer. *Cancer Treat. Rev.* 2004, 30, 193–204. [CrossRef]

156. Jiang, P.; Rao, E.Y.; Meng, N.; Zhao, Y.; Wang, J.J. MicroRNA-17-92 significantly enhances radioresistance in human mantle cell lymphoma cells. *Radiat. Oncol.* 2010, 5, 100. [CrossRef]

157. Ummanni, R.; Teller, S.; Junker, H.; Zimmermann, U.; Venz, S.; Scharf, C.; Giebel, J.; Walthier, R. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. *FEBS J.* 2008, 275, 5703–5713. [CrossRef]

158. White, E.; Mehnert, J.M.; Chan, C.S. Autophagy, metabolism, and cancer. *Clin. Cancer Res.* 2015, 21, 5037–5046. [CrossRef]

159. Mizushima, N.; Ohsumi, Y.; Yoshimori, T. Autophagosome formation in mammalian cells. *Cell Struct. Funct.* 2002, 27, 421–429. [CrossRef]

160. Tam, S.Y.; Wu, V.W.; Law, H.K. Influence of autophagy on the efficacy of radiotherapy. *Radiat. Oncol.* 2017, 12, 57. [CrossRef] [PubMed]

161. Yang, Y.; Yang, Y.; Yang, X.; Zhu, H.; Guo, Q.; Chen, X.; Zhang, H.; Cheng, H.; Sun, X. Autophagy and its function in radiosensitivity. *Tumour Biol.* 2015, 36, 4079–4087. [CrossRef] [PubMed]

162. Hu, L.; Wang, H.; Huang, L.; Zhao, Y.; Wang, J. Crosstalk between autophagy and intracellular radiation response (Review). *Int. J. Oncol.* 2016, 49, 2217–2226. [CrossRef] [PubMed]

163. Sharma, K.; Le, N.; Alotaibi, M.; Gewirtz, D.A. Cytotoxic autophagy in cancer therapy. *Int. J. Mol. Sci.* 2014, 15, 10034–10051. [CrossRef] [PubMed]

164. Wu, S.Y.; Liu, Y.W.; Wang, Y.K.; Lin, T.H.; Li, Y.Z.; Chen, S.H.; Lee, Y.R. Ionizing radiation induces autophagy in human oral squamous cell carcinoma. *J. BUON* 2014, 19, 137–144. [PubMed]

165. Kang, R.; Zeh, H.J.; Lotze, M.T.; Tang, D. The Beclin 1 network regulates autophagy and apoptosis. *Cell Death Differ.* 2011, 18, 571–580. [CrossRef]

166. Rothenberg, C.; Srinivasan, D.; Mah, L.; Kaushik, S.; Peterhoff, C.M.; Ugolino, J.; Fang, S.; Cuervo, A.M.; Nixon, R.A.; Monteiro, M.J. Ubiquilin functions in autophagy and is degraded by chaperone-mediated autophagy. *Hum. Mol. Genet.* 2010, 19, 3219–3232. [CrossRef]

167. Guo, X.; Xiao, H.; Guo, S.; Li, J.; Wang, Y.; Chen, J.; Lou, G. Long noncoding RNA HOTAIR knockdown inhibits autophagy and epithelial-mesenchymal transition through the Wnt signaling pathway in radioresistant human cervical cancer HeLa cells. *J. Cell. Physiol.* 2019, 234, 3478–3489. [CrossRef]

168. Reinhardt, H.C.; Schumacher, B. The p53 network: Cellular and systemic DNA damage responses in aging and cancer. *Trends Genet.* 2012, 28, 128–136. [CrossRef]

169. Maier, P.; Hartmann, L.; Wenz, F.; Herskind, C. Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. *Int. J. Mol. Sci.* 2016, 17, 102. [CrossRef]

170. Pawlik, T.M.; Keyomarsi, K. Role of cell cycle in mediating sensitivity to radiotherapy. *Int. J. Radiat. Oncol.* 2014, 89, 928–942. [CrossRef]

171. Yang, X.; Liu, W.; Xu, X.; Zhu, J.; Wu, Y.; Zhao, K.; He, S.; Li, M.; Wu, Y.; Zhang, S.; et al. Downregulation of long noncoding RNA UCA1 enhances the radiosensitivity and inhibits migration via suppression of epithelial-mesenchymal transition in colorectal cancer cells. *Oncol. Rep.* 2018, 40, 1554–1564. [CrossRef] [PubMed]

172. Fadaka, A.; Ajiboye, B.; Ojo, O.; Adewale, O.; Olayide, I.; Emuwochobere, R. Biology of glucose metabolism in cancer cells. *J. Oncol. Sci.* 2017, 3, 45–51. [CrossRef]

173. Yu, L.; Chen, X.; Sun, X.; Wang, L.; Chen, S. The glycolytic switch in tumors: How many players are involved? *J. Cancer* 2017, 8, 3430–3440. [CrossRef] [PubMed]

174. Marbaniang, C.; Kma, L. Dysregulation of glucose metabolism by oncogenes and tumor suppressors in cancer cells. *Asian Pac. J. Cancer Prev.* 2018, 19, 2377–2390.
175. Lin, J.; Xia, L.; Liang, J.; Han, Y.; Wang, H.; Oyang, L.; Tan, S.; Tian, Y.; Rao, S.; Chen, X.; et al. The roles of glucose metabolic reprogramming in chemo- and radio-resistance. *J. Exp. Clin. Cancer Res.* 2019, 38, 218. [CrossRef]

176. Zhou, J.; Xu, D.; Xie, H.; Tang, J.; Liu, R.; Li, J.; Wang, S.; Chen, X.; Su, J.; Zhou, X.; et al. miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α. *Cancer Biol. Ther.* 2015, 16, 846–855. [CrossRef]

177. Gu, Z.; Xia, J.; Xu, H.; Frech, I.; Tricot, G.; Zhan, F. NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase. *J. Hematol. Oncol.* 2017, 10, 1–11. [CrossRef]

178. Zhan, T.; Rindtorff, N.; Boutros, M. Wnt signaling in cancer. *Oncogene* 2017, 36, 1461–1473. [CrossRef]

179. Jackstadt, R.; Hodder, M.C.; Sansom, O.J. WNT and β-catenin in cancer: Genes and therapy. *Annu. Rev. Cancer Biol.* 2020, 4, 177–196. [CrossRef]

180. El-Sahli, S.; Xie, Y.; Wang, L.; Liu, S. Wnt signaling in cancer metabolism and immunity. *Cancers* 2019, 11, 904. [CrossRef]

181. Yang, Y.; Zhou, H.; Zhang, G.; Xue, X. Targeting the canonical Wnt/beta-catenin pathway in cancer radioresistance: Updates on the molecular mechanisms. *J. Cancer Res. Ther.* 2019, 15, 272–277. [CrossRef]

182. Navarro, F.; Lieberman, J. miR-34 and p53: New insights into a complex functional relationship. *PLoS ONE* 2015, 10. [CrossRef] [PubMed]

183. Schmitt, A.M.; Garcia, J.T.; Hung, T.; Flynn, R.A.; Shen, Y.; Qu, K.; Payumo, A.Y.; Peres-Da-Silva, A.; Broz, D.K.; Baum, R.; et al. An inducible long noncoding RNA amplifies DNA damage signaling. *Nat. Genet.* 2016, 48, 1370–1376. [CrossRef] [PubMed]

184. Chaudhary, R.; Lal, A. Long noncoding RNAs in the p53 network. *Wiley Interdiscip. Rev. RNA* 2017, 8, e1410. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).